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« The most beautiful thing we can experience is the
  mysterious. It is the source of all true art and science. »
             Albert Einstein
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1. SUMMARY
Human gene therapy can be defined as
the directed transfer of exogenous genes
or other nucleotide sequences into
somatic cells, for the purpose of
preventing, correcting or healing various
diseases. This novel approach to the
therapy of human disorders is based on
the realization that many previous
medical treatments have usually been
directed at the consequences of
causative defects or at disease symptoms
rather than at the underlying causes. The
field of gene therapy has been criticized
for promising too much and providing
too little during its first 10 years of
existence. However, several recent
successes achieved in human clinical
trials are demonstrating that the concept
of gene therapy is finally succeeding.
The basic challenge in gene
therapy is to develop approaches for
delivering genetic material to the
appropriate cells of the patient in a way
that is specific, efficient and safe. This
problem of "drug delivery," where the
gene is a drug, is particularly
challenging for genes which are large
and complex and require targeting to the
nuclei of cells. If genes are appropriately
delivered they can persist for the life of
the cell and potentially lead to a cure.
The enabling technology of gene
therapy is based on strategies for
delivering genes. To do this, special
gene delivery vehicles – also called
vectors – have been developed. Vectors
generally fall into two categories: viral
and nonviral. Viral vectors are generally
replication defective viruses with part or
even all of the viral coding sequence
replaced by that of therapeutic genes.
Currently, the majority of the vectors for
human gene therapy treatments is of
viral origin. However, humans have an
immune system able to fight off viruses,
and attempts to deliver genes via viral
vectors have been confronted by these
host response. This important drawback
of viral systems make synthetic vectors
an attractive alternative, especially when
readministration of the therapeutic
genetic material may be necessary.
However, nonviral vectors also have
important disadvantages, including their
low efficacy and their transient gene
expression.
In the present study, a novel
technique to improve both the efficiency
and the specificity of nonviral vectors is
described. This new gene transfer
technology has been called Steroid
Mediated Gene Delivery (SMGD). In
particular, the possibility to exploit the
shuttling action of nuclear receptors to
facilitate the nuclear uptake of DNA has
been explored. The SMGD has been
modelled with the well characterized
glucocorticoid receptor system. The
rationale was to decorate transgenes
with steroids. To this purpose, special
bifunctional steroid derivatives all
composed by a steroid molecule
covalently linked to DNA interacting
compound have been synthesized. The
final aim of this work was to test the
feasibility of the SMGD using the
steroid derivative DR9NP, which has
been ultimately selected from the initial
collection of synthetic conjugates. This
study clearly demonstrates that the
transfer of steroid-decorated transgenes
is selectively enhanced in presence of
the glucocorticoid receptor. This work is
the first that shows that nuclear
receptors can be exploited as gene
transfer vehicles. The SMGD approach
can now be extended to other ligands
that interact with nuclearly-shuttling
intracellular  receptors and offers
thereby an additional selective
advantage to the gene transfer-based
treatment of somatic tissues that express
specific steroid receptors.
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2. INTRODUCTION
2.1. HUMAN GENE TRANSFER
2.1.1. "GT 2000": human gene
transfer between life and death1
In the last twelve months, the gene
therapy field has been marked by two
events that have led the scientific
community into contrasting emotions.
In fact, we could experience both the
first patient died of a gene transfer
treatment2 and the first two patients
successfully cured with gene therapy3.
Why did Jesse Gelsinger die? And why
did it take apparently so long to obtain
a success in a clinical trial? Based on
the reactions and comments of the
scientific community, I will try to
answer these important questions. I
will also mention some recent
achievements that clearly demonstrate
that after a decade of frustrations, the
concept of human gene therapy may be
finally succeeding.
In September 1999, a relatively
healthy 18-year-old man with an
inherited enzyme deficiency died 4
days after doctors - under the guide of
James Wilson4 - injected a genetically
altered virus into his liver. Since
nobody did fully understand what went
wrong, no final conclusion has been
made. However, some important
                                                          
1 "GT 2000" is an abbreviation for Gene
Therapy in year 2000
2 For a recent commentary see: Eliot Marshall,
Gene Therapy death prompts review of
adenovirus vector, Science 286, 2244-45
(1999)
3 Cavazzano-Calvo et al., Gene therapy of
human severe combined immunodeficiency
(SCID)-X1 disease, Science 288, 669-672
(2000)
4 Institute of Human Gene Therapy, University
of Pennsylvania
considerations have emerged. It seems
that a central factor in the tragic events
that led to Gelsinger's death was the
high-dose of injected viral particles.
Wilson and his colleagues had given
Gelsinger 38 trillions adenoviral
particles, the highest dose in that 18-
patients trial, hoping to get enough
functioning transgene into his liver.
However, only 1% of the transferred
genes reached the target cells and none
of the patients in the trial showed
significant gene expression.
Furthermore, the viral particles
invaded not only the intended target,
but many other organs. This triggered
an activation of innate immunity
followed by a systemic inflammatory
response. This reaction brought
Gelsinger first into a coma and later to
death.
Why were not the high-dose
effects foreseeable, and why were so
few genes transferred? Wilson does not
know why the adenoviral vectors
worked so badly in humans, since
animal trials had indicated much
higher transduction rates. In regard to
the high toxicity of the viral particles,
Wilson suggested that Gelsinger's
immune response was an anomaly.
Wilson's collaborators found indeed
that Gelsinger's bone marrow was
severely depleted of erythroid
precursor blood cells, suggesting the
presence of an undetected genetic
condition or a viral infection, either of
which might have triggered the harsh
immune response. Most gene therapists
that analyzed the case agreed that
Gelsinger's reaction was unusual. At
that point, his death was considered
only an accident. However, a
subsequent investigation perfomed by
the Food and Drug Administration
resulted in the detection of important
"deviations" from the protocol in
Wilson's conduct of the clinical trial. It
is still unknown whether those
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"deviations" had any influence on
Gelsinger's death. However, everybody
agrees that the presence of such
irregularities is unaccetable and could
finally lead to irreversible damages to
the whole gene therapy field.
The most encouraging and long
expected good news came only six
months later. In fact, in April 2000 a
French research team - headed by
Alain Fischer5 - reported the
successfull treatment of two infants
suffering from severe combined
immunodeficiency (SCID). Mutations
in several different genes of immune
cells can result in SCID. The first gene
therapy trials treated patients suffering
from a type of SCID caused by a
deficiency in the enzyme adenosine
deaminase (ADA)6. In these trials, the
investigators inserted a normal copy of
the ADA gene (carried in a retroviral
vector) into mature T-lymphocytes and
later into bone marrow stem cells. In
addition, the patients were always
administered with PEG-ADA, a
polyethylene glycol-conjugated ADA
enzyme preparation that reduces the
levels of the toxic molecule
deoxyadenosine in ADA-deficient
patients. The majority of the patients
treated in these first trials have not
been significantly helped. An
amelioration of the symptoms occured
in the first patient (Ashanti de Silva)
even treated with gene therapy.
However, for ethical and safety
reasons the investigators never stopped
administreting PEG-ADA. Therefore,
the contribution of the gene therapy
                                                          
5 INSERM, Hôpital Necker-Enfants Malades,
Paris
6 (1) R.M. Blaese et al., T lymphocyte-directed
gene therapy for ADA-SCID: initial trial
results after 4 years.Science 270, 475-480
(1995); (2) C.Bordignon et al., Gene therapy in
peripheral blood lymphocytes and bone
marrow for ADA- immunodeficient patients,
Science 270, 470-475 (1995)
treatment alone could never be
monitored. In Fischer's clinical trial,
the two treated patients had a X-linked
form of SCID (SCID-X) caused by a
mutation in the gene encoding the γc
subunit, a component of certain
cytokine receptors. Fisher and
collaborators took hematopoietic stem
cells from the infants bone marrow and
incubated the cells ex vivo with a
retroviral vector carrying the γc gene.
The transduced stem cells were then
transfused back into the SCID-X1
patients. Clinically, the two patients
improved considerably and were able
to leave the hospital and go home only
3 months after the treatment!
 Why are the results of Fisher
and collaborators more encouraging
than those from the earlier experiments
that treated ADA-deficient SCID
patients?7 Unlike the earlier gene
therapy trials, the SCID-X1 patients
did not have to be administered  with
PEG-ADA. The concomitant
administration of PEG-ADA is
believed to lessen the potential growth
advantage of ADA gene-corrected
cells8. Still unpublished results indicate
indeed that ADA-deficient SCID
patients can be cured in absence of
PEG-ADA9. Therefore, the decision to
never stop the administration of PEG-
ADA in earlier gene therapy trials,
even if ethically correct could have
played a major role in the failure of the
treatments.
In addition to the success
achieved with gene therapy in the
treatment of SCID, recent publications
                                                          
7 For a recent commentary see: W. French
Anderson, The best of times, the worst of times,
Science 288, 627-629 (2000)
8 D.B. Kohn et al., T lymphocytes with a normal
ADA gene accumulate after transplantation of
transduced autologous umbilical cord blood
CD34+ cells in ADA-deficient SCID neonates,
Nature Medicine 4, 775-780 (1998)
9 Claudio Bordignon, ESGT annnual meeting,
October 2000, Stockholm
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reported significant progress in the
treatment of hemophilia10,
cardiovascular diseases11 and critical
limb ischemia12. Further publications
described the almost incredible
efficacy of novel or improved gene
therapy tools, such as ribozymes13,
chimeraplasts14 and "gutless"
adenoviral vectors15. These new tools
will probably enable gene therapists to
develop safer and more specific
clinical treatments. Major new
technolgies had failures and
disappontments. But gene therapy, like
every major innovation, will succeed
with time.
2.1.2. The need of efficient gene
delivery systems
Conceptually, gene therapy involves
the identification of a disease to cure
and its related potential genetic target.
The subsequent steps are the
identification of the appropriate cell
types to treat and the development of a
                                                          
10 M.A. Kay, Evidence for gene transfer and
expression of factor IX in haemophilia B patients
treated with an AAV vector, Nature Genetics 24,
257 (2000)
11 M. Isner et al., Therapeutic angiogenesis for
heart failure, Nature Medicine 5, 491-492 (1999)
12 I. Baumgartner, Constitutive expression of
phVEGF165 after intramuscular gene transfer
promotes collateral vessel development in
patients with critical limb ischemia, Circulation
97, 1114-1123 (1998)
13 A.S. Lewin, Ribozyme rescue of photoreceptor
cells in a transgenic rat model of autosomal
dominant retinitis pigmentosa, Nature Medicine
4, 967-970 (1998)
14 R.J. Bartlett, In vivo targeted ripair of a point
mutation in the canine dystrophin gene by a
chimeric RNA/DNA oligonucleotide, Nature
Biotechnology 18, 615-622 (2000)
15 Morral et al., Administration of helper-
dependent adenoviral vector and sequential
delivery of different vector serotype for long-
term liver directed gene transfer in baboons,
PNAS, 22, 12816-21 (1999)
suitable way to get enough of the
therapeutic genetic material
specifically into these cells. In practice,
considerable obstacles have emerged,
mostly caused by the inefficacy of
current gene delivery systems. All of
the current gene transfer systems - also
called vectors - have some limitation.
The "perfect" vector does not exist yet
and will probably never exist (see
Figure 1). The choice of the vector is
often dictated by the aim of the
treatment. If the expression of a gene is
required for only a short time (e.g.,
expression of a toxic protein in cancer
cells), then the adenoviral vectors are
ideal. If a sustained expression is
needed (such as in most genetic
diseases), then integrating vectors such
as retroviruses or adeno-associated
viruses (AAV) are suitable candidates.
If a vaccination against a particular
antigen is required, then no particular
vector is required and the injection of
naked plasmid DNA may be sufficient.
An "ideal" vector may have
properties of both viral and synthetic
gene transfer systems, and it should
include:
• the ability to transfer genetic
material with high efficiency
• the capacity to target the desired
type of cells (specificity)
• the ability to integrate in a site-
specific location in the host
chromosome, or to be successfully
maintained as a stable episome
(persistence)
• the ability to target non-dividing
cells (somatic cells)
• no components that elicit an
immune response
• an unlimited packaging size
• convenience, reproducibility and
biosafety compliance of production
• high concentration, allowing many
cells to be infected
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• an inducible transcriptional unit for
regulated gene expression.
Although such a vector isn't available,
all of these properties exist,
individually, in disparate delivery
systems. The features of some of the
most common gene transfer vectors are
listed in Table 1.
Table 1 does not include the most
innovative viral vectors. Among these,
particularly interesting is the
possibility to combine the advantages
of two independent viruses in one
single vector. As an example, hybrid
viral vectors that combine the great
gene transfer efficiency of
adenoviruses and the integration
capacity of retroviruses have been
proposed16. Similarly, an hybrid HSV-
AAV vector, that combines the large
packaging capacity of HSV and the
integration ability of AAV has also
been proposed17. Other revolutionary
viral systems are the so-called
"gutless" (or helper-dependent)
adenoviral vectors. These adenoviruses
are devoided of all viral coding
sequences and are therefore uncapable
to express any viral protein. A recent
report described their efficacy after
liver-directed gene transfer in
baboons18. The authors reported long-
term expression (longer than a year!)
and reduced immunogenicity and
toxicity. By looking at the rapid
evolution of adenoviral vectors, we can
                                                          
16 Feng et al, Stable in vivo gene transduction
via a novel adenoviral/retroviral chimeric
vector, Nature Biotechnology, 15, 866-870
(1997)
17 Fraefel et al., Gene transfer into hepatocytes
mediated by helper virus-free HSV/AAV
hybrid vectors, Mol Med, 3, 813-825, (1997)
18 Morral et al., Administration of helper-
dependent adenoviral vector and sequential
delivery of different vector serotype for long-
term liver directed gene transfer in baboons,
PNAS, 22, 12816-21 (1999)
envisage similar improvements for
similar gene transfer systems.
The new generation of viral
vectors is probably still at its primitive
stage. However, these innovations will
probably enable vectors to stay
competitive for certain in vivo
treatments. In fact, new therapeutical
procedures such as stem cell therapy
are rapidly emerging. If the
expectations related to stem cells will
become reality, soon their ex vivo
cultivation and their reimplantation
will enable the regeneration of various
tissues. In presence of a genetic
disorder, the corresponding correction
could be easily obtained with
conventional (inefficient!) gene
transfection systems and subsequent
selection of pre-characterized
recombinant cell clones. The most
optimists even envisage the
reconstruction of entire organs starting
from a population of explanted bone
marrow cells. Stem cells are such
powerful tools that risk to render
obsolete most of the efforts undertaken
to obtain high efficiency gene delivery
vectors. Those latter, would be
required only for treatments that do not
aim the use of stem cells, such as acute
treatments (e.g., organ transplantations,
infections) and correction of gain-of-
function disorders (e.g., cancers, auto-
immune disorders).
2.1.3. Viral vs. nonviral vectors
Vectors for gene therapy applications
generally fall into two categories: viral
and nonviral. They primarily differ in
their assembling process. In fact, viral
vectors are produced in cells, whereas
nonviral vectors are assembled in a test
tube. Viral vectors are generally
replication defective viruses with part
or even all of the viral coding sequence
- 12 -
replaced by that of therapeutic genes.
The major use of viral vectors for
human gene therapy applications is
mostly due to their superior gene
transfer efficiency (80-99% of targeted
cells express the transgene), if
compared to that of nonviral vectors
(0.5-20%). Other features that make
them the vectors of choice for clinical
applications are their ability to
integrate in the host genome (retroviral
and AAV vectors) and their capacity to
persistently express the transgene
(lentiviruses, AAV and HSV).
However, humans have an immune
system able to fight off viruses, and the
attempts to deliver genes in viral
vectors have been confronted by these
host responses. Other problems of viral
vectors include insufficient
pharmaceutical quantities (low viral
titers), toxicity, and the potential
emergence of replication-competent
viruses. The features of the major viral
vectors and a direct comparison with
nonviral vectors are reported in Table
1 (see 2.1.2.). Further important
aspects of gene transfer vectors are
extensively discussed in Paper 2 (see
3.2.).
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VECTOR Retroviral Adenoviral AAV HSV Non-viral
Genome type
and size
ssRNA
9 kb
dsDNA
36 kb
ssDNA
5 kb
dsDNA
150 kb
dsDNA
from plasmids
to BACs
Maximum
insert size
7 - 7.5 kb 30 kb 3.5 - 4 kb 15 -150 kb no limitation
Concentration
(partcles/ml)
low titer
106
high titer
1010
high titer
1011
high titer
1010
no limitation
Integration yes no yes no "no"
Duration of
expression
in vivo
"short"
(long  in
lentiviruses)
"short"
(long in
non-replicative
viruses)
long long
(mostly in
neurons)
short
Immunological
problems
few yes few yes "no"
Safety
problems
insertional
mutagenesis
inflammatory
response,
toxicity
insertional
mutagenesis,
low toxicity
cytotoxicity no
Targeting of
non-dividing
cells
only
lentiviruses
yes yes yes very
inefficient
Gene transfer
efficiency
high high high high low
TABLE 1. Comparison of properties of various vector systems. Abbreviations: AAV, adeno-
associated virus; HSV, herpes simplex virus; ssRNA, single stranded RNA; dsDNA, double
stranded DNA; ssDNA, single stranded DNA; kb, kilobases; BAC, bacterial artificial chromosome.
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2.2. NONVIRAL VECTORS FOR
GENE THERAPY
2.2.1. Brief desciption of current
nonviral vectors
The drawbacks of viral vectors (see
2.1.3.) make synthetic vectors an
attractive alternative. Followings are the
advantages of nonviral vectors:
• nonimmunogenicity
• low acute toxicity
• assembled for defined components
• convenience of production on a large
scale.
However, nonviral vectors also have
important disadvantages, including their
low gene transfer efficiency and their
transient gene expression. Many types of
nonviral vectors have been proposed. In
the current chapter I will briefly
summarize the most common nonviral
delivery systems.
2.2.1.1. Naked DNA
Ten years ago Wolff and co-workers
made a key discovery that led to an
increased interest in nonviral gene
transfer technologies19. These
investigators were the first to show that
muscle tissues could absorb
intramuscular injected naked plasmids,
leading to expression of the encoded
protein persisiting for periods of weeks
to several months. The original gene
transfer efficiencies were quite
satisfactory (5% of targeted cells
expressing the transgene). However,
higher expression levels were recently
achieved by delivering naked DNA
                                                          
19 Wolff et al., Direct gene transfer into mouse
muscle in vivo, Science 247, 1465-1468 (1990)
intravascularly under high pressure20 or
intratumourally via electrically enhanced
transfer21. Injection of naked DNA is
indicated for all the treatments that do
not need persistent transgene
expression22. Therapeutic expression
levels were indeed obtained after
intratumoral injection. The most
encouraging clinical results (among the
first achieved in human gene therapy!)
were obtained in the treatment of limb
ischemia after intramuscular injection of
plasmid encoding VEGF23. Because of
the semplicity and the relative low costs
of the approach, injections of DNA
encoding antigens from infectious
organisms are currently investigated for
immunization purposes. DNA-based
vaccinations have indeed a great
potential in the prevention of infectious
diseases (influenza, HIV, malaria,
hepatitis B) and cancer.
2.2.1.2. Gene gun
This physical method enables to shoot
DNA into cells via biolistic
bombardment. The gene gun uses gold
or tungsten particles coated with DNA.
An electric high-voltage discharge or a
sudden pressure accelerate the DNA-
coated particles to high velocity,
enhabling efficient penetration of single
cell layers in vitro or target organs in
                                                          
20 Budker et al., The efficient expression of
intravascularly delivered DNA in rat muscle,
Gene Therapy 5, 272-276 (1998)
21 Wells et al., Electroporation enhanced gene
delivery in mammary tumours, Gene Therapy 7,
541-547 (2000)
22 For a recent review see: Jon A. Wolff, Naked
DNA gene transfer in mammalian cells, book
chapter in The development of human gene
therapy, Cold Spring Harbor Laboratory Press
(1999)
23 Baumgartner et al., Constitutive expression of
phVEGF165 after intramuscular gene transfer
promotes collateral vessel development in
patients with critical limb ischemia, Circulation
97, 1114-1123 (1998)
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vivo. Although the DNA transfer is
relatively efficient, the major drawback
of this system is that the target tissues
must be surgically exposed.
2.2.1.3. Lipoplex
Lipoplexes are complexes formed by the
interaction of cationic liposomes and
DNA24. Liposomes generally consist of a
mixtures of positively charged lipids
(cationic lipids, e.g.: DOTMA) and
helper lipids (colipid, e.g.: DOPE). The
cationic lipid-mediated transfection is
also called lipofection. Lipoplexes are
capable of delivering functional nucleic
acid molecules into cultured cells with
relatively high efficiency. Cationic-
liposome formulations have three
properties that are particularly important
for efficient gene delivery. First,
liposomes spontaneosly condense with
DNA to form a complex in which up to
100 % of the DNA is entrapped. This
high entrapment efficiency is not limited
by the size of the DNA. Second, all
biological surfaces, including cultured
cell surfaces, carry a net negative charge.
Consequently, positively charged lipid
vescicles interact spontaneously with the
negatively charged cell surfaces.
Therefore, the liposomes-entrapped
genetic material is co-delivered to the
cell surface in a condensed form.
Finally, cationic lipids fuse with cell
membranes in a manner that allows the
entrapped DNA to enter the cytoplasm
and escape the degradative lysosomal
pathway. Several reports described the
ability of cationic lipids to deliver genes
also in vivo. The obtained results pushed
several gene therapists to test this gene
transfer approach in humans. Cationic
                                                          
24 For a recent review see: Philip L. Felgner,
Advances in synthetic gene-delivery systems
technology, book chapter in The development of
human gene therapy, Cold Spring Harbor
Laboratory Press (1999)
lipid-based delivery systems have indeed
been evaluated in phase I and phase II
clinical trials for the treatment of a
variety of different types of human
cancer and for the treatment of cystic
fibrosis.
2.2.1.4. Polyplex
Polyplexes are complexes formed by the
interaction of hydrophlic cationic
polymeres and DNA25. The polycations-
mediated transfection is also called
polyfection. The hydrophhilic polymers
are of two general types: the linear
polymers, such as polylysine and
spermine, and the branched chain,
spherical, or globular polycations such
as polyethyleneimine (PEI) or
dendrimers. An active area of scientific
research involves understanding and
controlling the DNA condensation and
packaging processes with these agents
and determing the structure of the
complexes. The cationic polymer-based
systems have been most widely
associated with the generation of
receptor-mediated gene delivery systems
(see 2.2.1.6).
2.2.1.5. Lipopolyplex
Lipopolyplexes are obtained by
incorporating polylysine (see 2.2.1.4.)
into lipoplex (see 2.2.1.3.) to form
ternary complexes. In lipopolyplexes
DNA is more tightly condensed
preventing the complex from further
aggregation and nuclease degradation.
Cationic and anionic lipopolyplexes
called LPDI and LPDII, respectively,
have been formulated and shown to be
effective in gene transfer.
                                                          
25 For a recent review see: A.Kichler et al.,
Polyethylenimines: a family of potent polymers
for nucleic acid delivery, book chapter in
Nonviral vectors for gene therapy, Academic
Press (1999)
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2.2.1.6. Receptor-targeted gene
transfer (RTGT)
Many cell surface receptors recognize
and bind specific extracellular ligands
with high affinity and in a specific mode.
Ligands can be proteins, peptides,
carbohydrates, vitamins and antibodies.
Some of these have been incorporated
into gene transfer systems for two major
reasons: (a) to target specific cell types
and (b) to enhance intracellular uptake
after binding to target cells26. Ligands
have been linked either directly to DNA,
to lipoplexes (see 2.2.1.3) or to
polyplexes (2.2.1.4). Similarly, the cell-
binding domains of viral vectors have
been modified to alter or broaden the
target cell specificity (change the viral
tropism).
RTGT systems generally contain
three molecular elements: (a) the DNA,
(b) a DNA-binding polycation and (c)
the targeting ligand which is covalently
linked to the polycation. Additional
elements can be incorporated that
modify the properties of the complex,
promoting intracellular release, nuclear
targeting or persistence of the introduced
transgene (see 2.2.1.7.). Wu and co-
workers linked the ligand
asialoorosomucoid to the DNA
condesing compound polylysine. This
conjugate could deliver DNA to
hepatocytes, by targeting the cell-
specific asialoglycoprotein (ASGP)
receptor27. Another ligand that has been
linked to different polycations was
transferrin, taking advantage of the
ubiquitously expressed transferrin
                                                          
26 For a recent review see: Cotten and Wagner,
Receptor-mediated gene delivery strategies,
book chapter in The development of human gene
therapy, Cold Spring Harbor Laboratory Press
(1999)
27 Wu et al., Receptor-mediated in vitro gene
transformation by a soluble DNA carrier system,
J.Biol.Chem. 262, 4429-4432 (1987)
receptor28. Tranferrin-mediated gene
transfer has been called
transferrinfection. Similar observations
were made with a variety of other
receptor-ligand systems, demonstrating
the feasibility of the RTGT approach.
Different in vivo applications of
RTGT have been tested, ranging from
direct injection into the target tissue to
systemic delivery. Local injection of
naked or complexed DNA directly into
tumors resulted in significant reporter
gene expression, with DNA-transferrin-
PEI complexes or adenovirus-linked
DNA-transferrin-polylysine complexes
being 10- to 100-fold more efficient than
naked DNA29. Systemic delivery of a
reporter gene complexed to a galactose-
modified polylysine resulted in
prolonged expression in rat
hepatocytes30. This observation
demonstrated the ASGP receptor could
be also targeted in vivo. The current
RTGT systems are very promising, but
still need to be improved. Better gene
transfer efficacies could be achieved by
incorporating additive biological
elements that would help to overcome
further extracellular and intracellular
barriers (see 2.2.2.).
2.2.1.7. Hybrid viral / nonviral vectors
Some new gene transfer systems have
combined the advantages of both viral
and nonviral vectors. A report described
the capability of adenovirus to promote
the gene transfer of transferrin-
                                                          
28 Wagner et al., Transferrin-polycation
conjugates as carriers for DNA uptake into cells,
PNAS 87, 3410-3414 (1990)
29 Kircheis et al., Polycation-based DNA
complexes for tumor-targeted gene delivery in
vivo, J.Gene Med (1999)
30 Perales et al., Gene transfer in vivo: sustained
expression and regulation of genes introduced
into liver by receptor-targeted uptake, PNAS 91,
4086-4090 (1994)
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polylysine conjugates31 (see 2.2.1.6.).
Adenovirus is indeed able to disrupt the
endosomal membrane, facilitating the
release of DNA into the cytoplasm and
avoiding its lysosomal degradation. A
further report descibed the construction
of a virus-like gene-transfer vehicle (also
called artificial virus), avoiding the
addition of intact viral particles. In fact,
Wagner and co-workers augmented the
gene transfer efficiency of transferrin-
polylysine-DNA complexes (see
2.2.1.6.) by adding an influenza virus
hemagglutinin HA-2 N-terminal
fusogenic peptide32. These DNA
complexes contained polylysine as
nucleic acid packaging module (see
2.2.1.4.), transferrin as receptor binding
module (see 2.2.1.6.) and influenza
peptides as endosomolytic module.
Together with hybrid viral vectors (see
2.1.2.), artificial viruses have the
potential to become the DNA transfer
tools of choice for future gene therapists.
2.2.1.8. DNA nanospheres
Nanospheres are particles formed by the
complexation of DNA with gelatin or
chitosan33. Gelatin, the denatured form
of collagen, is a polyampholyte that gels
below 35-40°C. Chitosan is a natural and
biodegradable polycationic linear
polysaccharide. In addition to the
benefits common to other nonviral gene
delivery systems, characteritics unique to
nanospheres inlcude coencapsulation of
bioactive reagent and sustained release
                                                          
31 Curiel et al., Adenovirus enhancement of
trasferrin-polylysine-mediated gene delivery,
PNAS, 88, 8850-8854 (1991)
32 Wagner et al., Influenza virus hemagglutinin
HA-2 N-terminal fusogenic peptides augment
gene transfer by transferrin-polylysine-DNA
complexes: toward a synthetic virus-like gene-
transfer vehicle, PNAS 89, 7934-7938 (1992)
33 For a recent review see: Kam W. Leong.,
Biopolymer-DNA nanospheres, book chapter in
Nonviral vectors for gene therapy, Academic
Press (1999)
of DNA. The former raises the
possibility of combining drug and gene
therapy in one single vehicle, and the
latter may improve the tissue
bioavailability of DNA. In recent
studies34, similar general properties were
found for chitosan and PEI (see 2.2.1.4.).
Both formed stable complexes with
plasmid DNA, having a diameter of
approximatively 120nm and a positive
net charge (positive zeta potential).
Transfection experiments in cultured
cells resulted in similar reporter
activities for the two systems. However,
in vivo PEI mediated 10-fold higher
expression levels than chitosan.
The efficacy of nanospheres has
been tested in further experiments. In
animal models, positive gene transfer
has been observed in the lung, muscle
and gastrointestinal tissues. Therein, the
measured reporter activities were
relatively low. Therefore, nanospheres
are particularly suitable for applications
that do not require high gene expression
levels, such as DNA vaccinations.
Nanospheres-protected DNA vaccines
could be more advantageous than simple
injections of naked DNA (see 2.2.1.1.).
In fact, free DNA is subject to
extracellular degradation and tissue
clearance. A local and sustained delivery
of DNA should increase the fraction of
DNA taken up by the target cell or
tissue. Targeting could be obtained by
attaching ligands externally to
nanospheres. As a matter of fact,
transferrin (see 2.2.1.6.) has been already
successfully linked to chitosan-DNA
complexes. Another type of nanosphere-
based immunization that is particularly
promising is the oral administration of
food allergenes. In a recent report, the
oral delivery of the dominant peanut
allergen gene provided immunologic
                                                          
34 Holly Guan, Chitosans as gene delivery
systems, Monte Verità Workshop on Gene and
oligonucleotide delivery of therapeutic and
vaccines, 18-23 April 1999
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protection and reduced anaphylaxis in a
murine model of peanut allergy35.
Therefore, this simple
immunoprohylactic strategy could
become the treatment of choice for the
often fatal food allergies, that are very
common and currently without an
effective treatment.
2.2.2. Barriers that a vector must
overcome
The in vivo applications of nonviral
vectors remain limited mainly because of
their low gene transfer efficiency. The
obstacles to efficient gene delivery and
expression can be described in terms of
"barriers". In the current chapter I will
focus on the currently identified
extracellular and intracellular barriers.
2.2.2.1. Extracellular barriers
The extracellular barriers are the
obstacles that the delivered genetic
material encounters before it reaches its
target cell.  They are particularly
important for in vivo gene transfer
procedures. The main barriers are:
• opsonins
• phagocytic cells
• extracellular matrix
• degradative enzymes
• other anatomical barriers
Opsonins are serum proteins
(complement system, neutralizing
antibodies) that stick to the vector,
inactivating the transgene and its carrier.
Phagocytes are cells capable of
engulfing and actively digesting the
invading particles. Extracellular
matrices are polymerized proteins and
                                                          
35 Roy et al., Oral gene delivery with chitosan-
DNA nanoparticles generates immunologic
protection in a murine model of peanut allergy,
Nature Medicine 5 (4), 1999
carbohydrates that are present between
cells protecting plasma membranes.
These matrices are particularly difficult
to overcome for large DNA vehicles.
The extracellular fluid is rich in DNases
that can rapidly digest unprotected DNA.
Finally, examples of anatomical barriers
are the skin and the blood-brain barrier.
2.2.2.2. Intracellular barriers
The intracellular barriers are the
obstacles that a delivered transgene
encounters once it reaches its target cell.
They are important for both in vitro
(cultured cells)  and in vivo gene transfer
procedures. By overcoming these
barriers, the vectors will finally enable
the transgene to enter the nucleus in
order to be transcribed. The main
intracellular barriers are:
• the plasma membrane
• the cytoplasm
• the nuclear envelope.
Current nonviral vectors are generally
designed to allow the genetic material to
cross the plasma membrane with high
efficiency. However only a small portion
of the delivered nucleic acids undergoes
nuclear translocation.36 Cytosolic
obstacles to nuclear accumulation are the
entrapment of DNA in the
endolysosomal compartment, the
degradation of DNA by nucleases and
the DNA sequestration by still
uncharacterized cellular structures.
However, the major intracellular barrier
for successful gene transfer is
represented by the nuclear envelope (see
2.2.3.).
                                                          
36 Zabner et al., Cellular and molecular barriers
to gene transfer by a cationic lipid, J Biol Chem
270, 18997-9007 (1995)
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2.2.3. Nuclear transport of exogenous
DNA
2.2.3.1. Nucleocytoplasmic transport
There is a very dense traffic across the
nuclear membrane. Every minute several
millions RNA and protein molecules are
transported into the nucleus and vice
versa. This intense traffic is regulated by
special transport factors that are called
importins and exportins. These factors
are continously shuttling between the
cytoplasm and the nucleus, passing
through the Nuclear Pore Complex
(NPC), a large protein structure
embedded in the nuclear envelope37. The
NPC contains a central channel with a
diameter of 9 nm that allows free
diffusion of small proteins (<50 kD).
Larger particles or molecules (up to 25
nm) can be transported only in presence
of appropriate signatures, such as the
Nuclear Localization Signals (NLS).
One of the first NLS was identified in
the SV40 large-antigen and has the
sequence PKKKRKV. Such NLS is first
recognized by importins in the
cytoplasm. The formed complex is then
transported into the nucleus via an
energy-dependent reaction. Because
nondividing cells are poorly
transfectable by nonviral vectors and
transfection particles generally have a
diameter larger than 25 nm, it was
postulated that nuclear uptake occurs
preferentially in cells that are entering
mitosis, consequently to breakdown of
the nuclear envelope38.
                                                          
37 For a recent review see: Nigg, E.A.,
Nucleocytoplasmic transport: signals,
mechanisms and regulation, Nature 386, 779-787
(1997)
38 Wilke et al., Efficacy of a peptide-based gene
delivery systems depends on mitotic activity,
Gene Therapy 3, 1133-1142 (1996)
2.2.3.2. The DNA nuclear import is
inefficient
Already in 1980 the nuclear import step
has been recognized to be a major barrier
for gene expression. In a pioneering
experiment, Capecchi and co-workers
reported that 50-100 % of thymidine
kinase (TK)-deficient mouse fibroblast
cells expressed TK, after having injected
a TK encoding plasmid into their nuclei.
In contrast, cytoplasmic injection of over
1000 cells did not result in any
detectable TK activity39. Further reports
confirmed this result in other cell lines.
However, in 1995 the laboratory of Jon
Wolff surprisingly reported that
cytoplasmically injected plasmid DNA
can enter postmitotic and thereby intact
nuclei40. In the same report there were
even some evidences about the ability of
plasmids to enter nuclei through the
NPC. How does a 5 kilobases large
plasmid with a molecular weight of more
than 3 megadaltons enter the NPC? Such
a plasmid would have a diameter of at
least 100nm in its compacted globular
form41. Therefore, very likely the
plasmid is struggled through the NPC in
its unwinded decondensed form by a still
unknown process. Since the plasmid
nuclear entry is restricted to a few
somatic cell types, it could be that in
these cells particular shuttling factors
(import machinery components?,
transcription factors?) stick to DNA
facilitating its nuclear transport. It could
also be, that under certain physiological
conditions these cells have more
                                                          
39 Capecchi, M.R., High efficiency
transformation by direct microinjection of DNA
into cultured mammalian cells, Cell 22, 479-488
(1980)
40 Dowty et al., Plasmid DNA entry into
postmitotic nuclei of primary rat myotubes,
PNAS 92, 4572-4576 (1995)
41 For a recent review see: Lasic Dan D..,
Structure and structure-activity relationships of
lipid-based gene delivery systems, book chapter
in Nonviral vectors for gene therapy, Academic
Press (1999)
- 20 -
permessive nuclear pores, that enable the
entry of DNA into the nuclei.
Also the necessary steps that
enable transfected DNA to reach the
nucleus are not yet understood. In
particular, is still unknow where and
when DNA is released from its carrier
(e.g., cationic lipids, polylysine, PEI). In
the cytoplasm of cultured cells, lipid-
DNA complexes have dimensions of
400-800 nm with 5 to 20 plasmids
complexed in a single lipid-DNA
particle. Obviously, for entering nuclear
pores, plasmids have to be released from
those huge complexes. However, a
recent report described the detection of
500nm large PEI-DNA complexes in the
nuclei of non-dividing cells, indicating
that in some cases complexed plasmids
can enter the nucleus42. Understanding
the DNA nuclear import mechanism in
detail is of primary importance and
would probably allow the design of more
efficient nonviral vectors.
2.2.3.3. NLS-mediated gene transfer
As previously discussed (see 2.2.2.2.),
the nuclear envelope has been identified
to be the major barrier for the gene
transfer of foreign DNA. One of the
most promising approaches that has been
recently proposed to overcome this
barrier, is the covalent linkage of NLS
peptides (see 2.2.3.1.) to plasmid DNA.
A recent report described indeed a
nuclear accumulation of NLS-conjugated
DNA fragments in digitonized cells (see
2.4.4.)43. A significative enhancement of
expression of NLS-coupled transgenes
                                                          
42 Labat-Moleur et al., An electron microscopy
study into the mechanism of gene transfer with
lipopolyamines, Gene Therapy 3, 1010-1017
(1996)
43 Sebestyén et al., DNA vector chemistry: the
covalent attachment of signal peptides to plasmid
DNA, Nature Biotechnology 16, 80-85 (1998)
has been also recently reported44. Each
report described a different strategy for
linking NLS to DNA. These strategies
will be extensively described and
discussed in Paper 1 (see 3.1.) and in
chapters 2.4.3 and 2.4.4.
2.2.3.4. Viral strategies for DNA
nuclear transport
Viruses employ a variety of strategies to
enter the nuclear pore45. Deciphering
these strategies and understanding the
differences between naked and viral
DNA transport could give new clues to
manipulate the cytoplasmic and nuclear
transport steps in many nonviral gene
delivery protocols. In the current chapter
I will briefly discuss some general
features of viral nuclear import. I will
also mention few selected nuclear
transport strategies adopted by some
virus families and by some plant
pathogens.
Both Adenoviruses and Herpes
Simplex Viruses are able to efficiently
infect non-dividing cells46. To this
purpose, they have evolved some
common strategies to transport their
large genomes (36 and 150 kb,
respectively) into the nucleus of host
cells: (1) use microtubule-associated
motor mechanisms to move towards the
nucleus, (2) associate to NLS-carrying
                                                          
44 (1) Zanta et al., Gene delivery: a single nuclear
localition signal peptide is sufficient to carry
DNA to the cell nucleus, PNAS  96, 91-96
(1999); (2) Branden et al., A peptide nucleic
acid-nuclear localization signal fusion that
mediates nuclear transport of DNA, Nature
Biotechnology 17, 784-787 (1999)
45 For a recent review see: Whittaker G.R. and
Helenius A., Nuclear import and export of
viruses and virus genomes, Virology 246, 1-23
(1998)
46 For a recent review see: Sebestyén, M.G. and
Wolff, J.A., Nuclear transport of exogenous
DNA, book chapter in Nonviral vectors for gene
therapy, Academic Press (1999)
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proteins for nuclear targeting, (3) target
the NPC in a protected, wrapped form,
(4) transport the genome in a linear form
for efficient transport trough the NPC.
Some of these strategies should be
adopted in the future for the
development of better nonviral vectors.
As a matter of fact, a recent report
described a 1000-fold enhancement of
transfection obtained with linearized
NLS-coupled transgenes (see 2.4.3.).
Another intriguing nuclear import
strategy present in nature is the one
adopted by the plant pathogen
Agrobacterium tumefaciens. The
Agrobacterium single-stranded DNA
intermediate T-strand is composed of a
complex (12.6 nm x 3.6 µm) with a
single VirD2 peptide at its 5'-end and
multiple VirE2 peptides along its length.
Both VirD2 and VirE2 contain NLSs,
and it is thought that the DNA docks to
the NPC via the VirD2 peptide, at which
point transport is initiated. The multiple
VirE2 peptides then mediate the
translocation of the 20 kb large DNA
fragment through the NPC. One day
components of this extremely efficient
plant pathogen may be mixed with
elements of viral gene delivery systems
to create an optimal virus-like gene
transfer vehicle (see 2.2.1.7.). As a
matter of fact, a DNA fragment
complexed to VirD2 and VirE2 has been
already successfully imported into the
nucleus of mammalian cells47.
                                                          
47 Ziemienowicz et al., Import of DNA into
mammalian nuclei by proteins originating from a
plant pathogenic bacterium, PNAS 96, 3729-33
(1999)
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2.3. STEROID  MEDIATED GENE
DELIVERY (SMGD)
2.3.1. Steroid Hormone Receptors
Nuclear Receptors48, such as the
receptors for steroids and thyroid
hormones, retinoids and vitamin D3, are
ligand-inducible transcription factors
present in vertebrates, arthropods and
nematodes. They regulate complex
physiological events that trigger key
steps during development, control
maintenance and homeostasis, and
induce or inhibit cellular proliferation,
differentiation or death. To date, more
than 150 different proteins have been
identified as members of the nuclear
receptor superfamily, which is often
further divided into steroid and
nonsteroid (thyroid/retinoid/vitamin D)
receptor families. Steroid hormone
receptors (SHRs) include the
Glucocorticoid Receptor, the
Mineralocorticoid Receptors, the
Progesterone Receptor, the Androgen
Receptor and the Estrogen Receptor.
SHRs exert their influence during
embryonic development and in adult
homeostasis as hormone-activated
transcriptional regulators. Their modular
structure, consisting of a DNA binding
domain (DBD), nuclear localization
signals, a ligand binding domain (LBD)
and several transcriptional activation
functions (AFs), is conserved with other
members of the nuclear receptor
superfamily. Unique to the SHRs is their
ability upon activation to bind to
palindromic DNA sequences, called
hormone response elements (HREs),
exclusively as homodimers.
In absence of hormones, SHRs are
generally localized in the cytoplasm
associated with a large multiprotein
complex of chaperones which maintains
                                                          
48 For a comprehensive review see: Mangelsdorf
et al., The Nuclear Receptor Superfamily: The
Second Decade. Cell 83, 835-877 (1995).
the receptors in an inactive but ligand-
accessible conformation. Upon ligand
binding, the receptors become
conformationally active. Activated SHRs
dissociate from the chaperones,
translocate into the nucleus, bind to
specific HREs and interact with
components of the basal transcriptional
machinery and with sequence-specific
transcription factors. Is not so clear
whether dissociated unligated SHRs are
then exported from the nucleus in the
cytoplasm. The shuttling of the receptors
between the cytoplasm and the nucleus
comprises an equilibrium which in
presence of steroids  is shifted towards
the nucleus.
2.3.2. The principle of SMGD:
Nuclear Receptors as vehicles for
DNA
One drawback of nonviral vectors is that
they do not allow DNA to be transported
into the nucleus efficiently (see 2.1.3.
and 2.2.3.2.). As discussed above (see
2.3.1.), SHRs are continously shuttling
between the cytoplasm and the nucleus.
Therefore, SHRs can be considered as
natural ferries for steroid molecules. A
question which consequently arises is
whether the shuttling propriety of the
SHRs could be exploited to improve the
nuclear uptake of DNA. In other words,
if a DNA molecule could be attached to
a steroid receptor, then the resulting
DNA/SHR complex should be
transported into the nucleus.
The initial idea soon gave rise to a
potential new gene transfer technology
which was called Steroid Mediated Gene
Delivery (SMGD). The concept of the
SMGD approach is illustrated in Figure
2.
Another factor limiting the
efficacy of gene transfer vectors is the
inability to target genes specifically to a
desired cell type. Most targeting
techniques developed to date enable
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DNA to be internalized into the
cytoplasm of the desired cell via specific
surface ligand docking (see 2.2.1.6.). A
strategy which has been neglected is the
possibility of specifically transferring
therapeutic genes into the nucleus of
particular cell types, regardless of how
the DNA is delivered to the cells. In this
context, the SMGD approach could
significantly improve the specificity of
nonviral vectors. In fact, the final
general aim of SMGD is to offer a
selective advantage to the therapeutic
treatment of cells that express a specific
steroid receptor. Examples of possible
targets are discussed in chapter 2.4.5.
2.3.3. The initial purposes of SMGD
The first nuclear receptor mentioned in
the context of SMGD was the
Mineralocorticoid Receptor (MR). The
original application of SMGD in humans
was in the context of a very rare illness
called Apparent Mineralocorticoid
Access (AME). Patients affected by
AME suffer from hypertension,
hypokalemia and sodium retention. This
illness is a monogenic disease and is
characterized by a defect in the gene
encoding 11β-hydroxysteroid
dehydrogenase49 (11β-OHSD). The
steroid hormones Cortisol and
Aldosterone have an equal affinity for
MR. 11β-OHSD inactivates Cortisol by
conversion to Cortisone conferring to
MR specificity for Aldosterone. This
biochemical reaction is only relevant in
mineralocorticoid target tissues,
especially in distal kidney tubular cells.
Thus, targeting 11β-OHSD to those cells
has the potential to cure patients affected
by AME. For that purpose, those cells
would be the suitable target for the
                                                          
49 The research team of our collaborator Prof.
Felix Frey has for many years studied the
kinetics and the dynamics of 11β-OH-
glucocorticoids.
selective gene delivery of 11β-OHSD. In
this context, the SMGD strategy could
be applied to achieve a selective transfer
of 11β-OHSD only in MR-positive distal
kidney tubular cells and not in the MR-
negative surronding cells. The success of
the applied gene therapy treatment could
be easily monitored by following urinary
potassium excretion and sodium
retention with increasing blood pressure
and the suppression of renin and
aldosterone.
Because of SMGD's initial purposes,
the first months of my PhD studies were
devoted to the identification of genomic
clones containing the 11β-OHSD gene.
For this purpose, I designed the
necessary detection probes which were
used to screen mouse and human P1
genomic libraries50. P1 clones are
derived from P1 bacteriophages and can
have DNA inserts of 100-110 kb. The
final aim was to identify clones which
spanned the whole locus surrounding the
6.2 kb 11β-OHSD gene. The use of large
genomic segments was thought to be
instrumental in view of the final clinical
approach, that was the transfer of the
whole locus in the target cells. The
presence of the 11β-OHSD's regulatory
sequences would have increased the
chance of a correct long-term expression
of the therapeutic protein. Luckily, the
library screening resulted in the
detection of three mouse and two human
positive clones.
As discussed later (see 2.4.5.), the
initial purposes of SMGD changed
during the time. In fact, althought AME
would have been a valid model to test
the feasibility of the SMGD approach in
humans, it had the big drawback of
being an illness readily curable with
conventional therapies. Furthermore the
incidence of AME is extremely low with
less than one hundred affected
individuals worldwide. This brought into
                                                          
50 The P1 library screenings were performed by
the company Genomic Systems Ltd.
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question the economic feasibility and
clinical relevance of developing a novel
therapeutic strategy for this particular
illness.
2.3.4. Modelling the SMGD with the
Glucocorticoid Receptor (GR)
Before starting to think in terms of a
clinical application, the initial step was
to demonstrate the overall feasability of
the SMGD approach. Although other
nuclear receptors could have been
chosen, the SMGD was modelled with
the well characterized Glucocorticoid
Receptor (GR) system, because the
necessary expression vectors, receptor
mutants, commercial ligands for
derivatization and the necessary know-
how51 were available. Of particular
importance was the availability of
chimeric GR-GFP proteins. GFP (green
fluorescent protein) is a polypeptide that
has intrinsic fluorescence when activated
by UV-light and can be easily followed
intracellularly by fluorescence
microscopy . The cellular localization of
the GR-GFP chimera in presence or
absence of ligands has been previously
studied in Ruscolab, confirming the
previously discussed shuttling propriety
of the Glucocorticoid Receptor52. The
simplicity of the developed assay (no
requirements of specific staining or
sequential antibody incubation as in the
case of epitope-tagged proteins) was
extremely useful in testing the nuclear
translocation potential of the synthesized
                                                          
51 The GR has been widely studied by Prof.
Sandro Rusconi who became involved in the
cloning and functional characterization of that
protein during his postdoctoral studies. He
continued this work when he returned to Zürich
and is pursuing these studies in his current
position in Fribourg.
52 Andrea Nawrocky, "Construction of
fluorescent GR chimeras to study receptor
localization in living cells", Diplomawork (1996)
by Prof. Rusconi, Institute of Biochemistry,
University of Fribourg
steroid derivatives (see also 2.3.5., 2.3.7.
and 3.1.).
Because of SMGD's initial
application using the Mineralocorticoid
Receptor (see 2.3.3.) and because of
conflicting reports regarding its shuttling
behaviour, I cloned GFP C-terminally of
MR and I studied the cellular
localization of the resulting MR-GFP
chimera. Surprisingly, I was unable to
observe any shuttling of the chimeric
protein. In absence and in presence of
Aldosterone, MR-GFP was localized in
both the cytoplasm and the nucleus.
Only two years later a report appeared53
in which the shuttling of a GFP-MR
chimeric protein (GFP cloned N-
terminally of MR) was clearly described.
Unfortunately, in that report the
construction of a MR-GFP chimera
(GFP cloned C-terminally) has not been
neither described nor discussed.
However, from my results it is possible
to speculate that the C-terminally
positioned GFP prevents the MR from
interacting correctly with the ligand or
with the nuclear import and/or export
machinery. This faulty interaction would
disable the MR-GFP chimera from
shuttling correctly. Interestingly, the
shuttling behaviour of GR can be
observed with GFP positioned either C-
or N-terminally.
2.3.5. The "first generation" of steroid
derivatives
To model the SMGD, we first had to
design and synthesize the necessary
molecules for the steroid-decoration of
plasmid DNA (see 2.3.2. for SMGD's
principle). In particular, we had to
develop special bifunctional steroid
derivatives composed of a steroid
                                                          
53 Fejes-Tóth et al., Subcellular localization of
mineralocorticoid receptors in living cells:
effects of receptor agonists and antagonists,
PNAS, 95, 2973-2978 (1998)
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molecule linked via a chemical spacer to
a DNA-interacting compound. For each
of these components, we had to take into
account a multitude of variables for the
design of the final steroid derivatives.
Some of these variables are listed in
Figure 3.
In this chapter, I will only mention the
variables that are relevant for the
understaning of my work. Other
variables will be discussed by some of
my collaborators in future publications54.
The big challenge in derivatizing a
ligand is to synthesize a molecule which
still retains a significant affinity for its
cognate receptor. In this context, the
ideal situation for designing a steroid
derivative would entail knowing the
three-dimensional structure of the
Ligand Binding Domain (LBD) of the
corresponding Steroid Hormone
Receptor (SHR). As discussed
previously (see 2.3.4.), we aimed to
model the SMGD with the
Glucocorticoid Receptor (GR).
Unfortunately, at that time no SHR LBD
crystal structure was available. However,
the LBD's crystal structure of both an
unliganded (RXRα) and a liganded
Nuclear Receptor (RARγ) had been
recently solved. Furthermore, just before
the beginning of the SMGD project, a
report appeared in which a sequence
alignment of all Nuclear Receptor LBD's
had been performed55. Based on the
available crystal structures and the
results of the alignment, the authors were
able to predict a common structure for
the LBD of all nuclear receptors. The
authors also proposed a model for the
ligand-binding interaction of GR with
Dexamethasone, a well know GR-
agonist. According to that model, the
hormone is totally wrapped around by
                                                          
54 Bernasconi A. et al., in preparation; Rebuffat
et al., in preparation.
55 Wurtz J.-M. et al., A canonical structure for
the ligand-binding domain of nuclear receptors,
Nature Structural Biology 3, 87-94 (1998).
polypeptide residues of the LBD, with
the exception of a little "hole" through
which the ligand can be approached
from outside. We had the chance to get
directly from the authors an electronic
version of that model. Since we were
convinced about its validity, we started
to design our first steroid derivatives
based on the modelled interaction. The
most favourable positions for steroid
derivatization seemed to be 4 and 6 (see
Figure 4), since a chemical group
attached to one of those positions would
have sticked out of the LBD's "hole".
With the help of experienced chemists56,
we started to investigate for possible
chemical reactions for the linkage of a
chemical spacer at those positions.
According to the chemists opinion, all
the possible reactions were particularly
complicated requiring sophisticated
reagents and apparatuses, difficult to
find even in well- equipped chemistry
laboratories. At that point, we seriously
started to doubt the feasibilty of any
derivatization at those chemical
positions.
The steroid derivatization of other
positions seemed to be less complicated.
In particular, postion 21 (see Figure 4)
seemed to be a good candidate, since
several GR-ligands for derivatization at
that particular position were available. In
this context, a former collaborator57 had
the idea to chemically link the DNA-
intercalating agent Ethidium Bromide at
position 21 of the steroid molecule
Cortisol-21-hemisuccinate. The resulting
compound was named Cortisol-21-
Ethidium (Cl-21-Et) and constitues the
prototype of our "very first" generation
of steroid derivatives58. As discussed
                                                          
56 Prof.Gossauer and Dr.Engel, Chemistry
Department, University of Fribourg
57 Dr. Ivo Galli, European Patent Office, The
Netherlands
58 The bifunctional molecules described and
tested in the first paper (see 3.1.) were arbitrarily
declared as "first generation" steroid derivatives.
In reality, these molecules are members of a
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later (see 2.3.6.), thanks to Cl-21-Et we
got the first encouraging results which
helped everybody to believe further in
the SMGD approach.
Thanks to the previously described
assay (see 2.3.4.), I observed that Cl-21-
Et was able to induce nuclear
translocation of GR. This observation
was an indirect proof about  the ability
of GR to bind to Cl-21-Et. Although
good news, this result was in contrast to
the GRs ligand-binding interaction
model. According to that model, a
substituent attached to position 21 would
point to the inner part of the LBD. In
fact, a steroid derivatization at position
21 would almost have an opposite
orientation with respect to subsituents
linked the most favourable positions 4
and 6 (see Figure 4). The answer to these
conflicting results appeared in a report
which described the crystal structure of
Estrogen Receptor's LBD, the first ever
solved for a SHR59. In this structure, the
positioning of the ligand was turned by
180° with respect to the model
previously proposed. Several months
later, the crystal structure of
Progesterone Receptor's LBD confirmed
the orientation of the hormone in the
ligand-pocket60, inducing us to
definetely give up the idea to derivatize
positions 4 and 6. Therefore, we
continued to derivatized the steroids at
position 21.
2.3.6. The first encouraging results
Cl-21-Et (see 2.3.5.) was the first steroid
derivative that was tested in combination
with other nonviral vectors. In a very
                                                                               
forth or even a fifth generation of steroid
derivatives !!!
59 Brzozowski et al., Molecular basis of agonism
and antagonism in the oestrogen receptor,
Nature, 389, 753-758 (1997)
60 Williams et al., Atomic structure of
progesterone complexed with its receptor,
Nature, 393, 392-396, (1998)
crude experiment, Cl-21-Et was simply
mixed with plasmid DNA carrying a
reporter gene. The resulting steroid-
DNA complex was then used for
transfection experiments, using different
gene transfer procedures. To measure a
possible "enhancement of transfection",
the expression levels of the steroid-
complexed and uncomplexed DNA were
compared in cycling cells which
naturally expressed high levels of GR.
We were very happy to observe that the
steroid-DNA complex mediated three to
four fold higher expression levels than
uncomplexed DNA, using Calcium
Phosphate as a transfection agent (see
Figure 5). Similar enhancements of
transfection were found by transfecting
the cells with Polyethylenimine (see
2.2.1.4.), indicating that the observed
effect was independent from the adopted
gene transfer procedure.
At that time we were very excited
about the obtained results. However, we
had no evidence that the enhancement of
transfection was GR-mediated, rather
than simply caused by the presence of
the many lipophilic steroid molecules in
the transfection cocktails. As a matter of
fact, several reports appeared in which
enhanced expression levels were
obtained, simply by adding steroids such
as Estradiol or Dexamethasone in the
transfection mixtures61. To exclude this
possibility, the expression levels of the
steroid-complexed and uncomplexed
DNA were compared in cells that do not
express functional GR. Therein, we did
not observe any enhancement of
expression. This result induced us to
think that the previously observed
enhancement of transfection was GR-
mediated. As discussed later (see 2.4.2.),
                                                          
61 Jain et al, Estradiol enhances gene delivery to
human breast tumor cells, J Mol Med, 76, 709-
714 (1998); Braun et al, In vitro and in vivo
effects of glucocorticoids on gene transfer to
skeletal muscle, FEBS, 454, 277-282 (1999);
Bernasconi et al, Cortisol increases transfection
efficiency of cells, FEBS, 419, 103-106 (1997)
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the true breakthrough came when
adenoviral vectors encoding GR were
available. These enabled us to develop
an experimental system in which cells
were externally supplemented with GR.
2.3.7. SMGD's "winning horse":
Dr.Wehrli!
For the very "first generation" of steroid
derivatives (see 2.3.6.) we attached the
hormone Cortisol to the DNA-
intercalating agent Ethidium. These
molecules, even if representing a first
heroic attempt to demonstrate the
feasibility of the SMGD approach, have
two big drawbacks. The first one, is the
very low affinity for the GR, that is a
hundred fold loss of affinity compared to
the natural ligand Cortisol. The second
one, is mediated by the nature of the
DNA-interaction. The fact the Ethidium
can not be covalently linked to DNA,
does not permit the determination of the
number of steroid molecules attached to
the steroid-decorated plasmid. We
solved the first problem by choosing a
ligand with a higher affinity for GR,
namely Dexamethasone. The second
problem was solved by changing the
nature of the DNA-interaction, that is by
linking the steroid derivative to DNA in
a covalent manner. For this purpose, we
chose Psoralen, a photoreactive molecule
that can be crosslinked to DNA by UV-
light irradiation.
The ideal steroid derivative needed
to be stable under typical cell culture and
physiological conditions. Therefore the
choice of the bonds which linked its
different components was particularly
critical. In this context, we had the big
chance to get the support of an
experienced chemist, Dr. Hans Wehrli.
Dr. Wehrli is a sixty years old chemist,
which worked for more than twenty
years for Ciba-Geigy. Because of the
reorganization within that company due
to its fusion with Sandoz62, Dr. Wehrli
was one of the victims of the "early
retirement program". Since he worked
for quite a while in the "steroid
chemistry department", we could not
expect a better collaborator. What a luck
for us and for him! The most important
innovation introduced by Dr. Wehrli,
was the introduction of two Urethane
bonds (see Figure 1B of Paper 1, in
chapter 3.1.) to link the chemical spacer
to the other two components of the
steroid derivatives, that is the hormone
molecule and the DNA-interacting
compound. By testing the Urethane bond
under different conditions, we were
amazed about its stability and its
resistance. These features were absent in
the "first generation" of steroid
derivatives (see 2.3.5.).
                                                          
62 In 1996, Ciba-Geigy fused with Sandoz giving
rise to the "giant" Novartis.
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2.4. DESCRIPTION AND
SIGNIFICANCE OF THE
PERSONAL CONTRIBUTIONS
2.4.1. The covalent attachment of
steroids to DNA
As previously discussed (see 2.3.7.), we
abandoned the strategy of producing
steroid-decorated plasmids via a DNA-
intercalating agent. Instead of Ethidium,
the "new generation" of steroid
derivatives had the crosslinking reagent
Psoralen as a DNA-interacting
compound. We synthesized a large
number of similar bifunctional steroid
derivatives. These molecules had either
Cortisol or Dexamethasone as a steroid
hormone molecule and differed in the
composition and in the lenght of their
chemical spacers. Out of this initial pool
of steroid derivatives, we selected a
compound composed of Dexamethasone
conjugated to Psoralen via a 8 atoms
long spacer, shortly denominated
DR9NP. The chemical structure of
DR9NP is showed in Figure 1B in
chapter 3.1.. Compared to the other
synthesized steroid derivatives, DR9NP
showed a better solubility in various
solvents and had a superior affinity for
the GR. In vitro binding studies
performed by my collaborators, revealed
indeed very similar dissociating
constants for DR9NP and the strong
binding hormone Dexamethasone.
Thanks to the previously described assay
(see 2.3.4.), I was able to observe that
DR9NP and Dexamethasone induced a
similar strong nuclear translocation of
GR. This observation is described in in
Figure 1C of Paper 1 (see 3.1.).
An important question still to be
answered was whether the steroid
derivatives having Psoralen as a DNA-
interacting compound could have been
attached to plasmid DNA. In this
context, the first molecule to be tested
was the steroid derivative "Cortisol-
Psoralen", shortly named CR5NP. To
analyze its crosslinking potential I first
UV-irradiated a plasmid DNA in
presence of CR5NP. The excess of
unreacted CR5NP molecules was
removed thanks to several organic
extractions and precipitation steps. The
irradiation and the purification
procedures were performed using the
same conditions described in the
literature for Psoralen. The treated
plasmid was linearized and analyzed by
alkaline gel electrophoresis. Under those
conditions, crosslinked DNA fragments
remain double stranded and are visible
as slow migrating bands, whereas
uncrosslinked DNA fragments become
single stranded and are visible as fast
migrating bands. I was very glad to
observe that the CR5NP-treated plasmid
migrated slower than the untreated
plasmid, indicating that CR5NP could
have been crosslinked to DNA. Similar
results were also found for other steroid
derivatives, demonstrating the potential
of steroid-conjugated Psoralen for the
covalent linkage of steroids to DNA.
Similar analysis have been
subsequently performed for the steroid
derivative DR9NP and are described in
Figure 3 of Paper 1 (see 3.1.). In
particular, a plasmid carrying a reporter
gene was UV-irradiated at different
concentrations of DR9NP. Therefore, I
obtained different steroid-decorated
plasmid preparations. The fact that
DR9NP was covalently linked to DNA
enabled me to estimate for each
preparation the average number of
steroid molecules attached to the
DR9NP-crosslinked plasmids. In a
parallel experiment, I also determined
for each preparation the residual reporter
gene activity. Since we were
crosslinking the plasmid randomly,
including the biologically active regions,
we were expecting an activity loss for a
fraction of the plasmids. By irradiating
the plasmids at low DR9NP
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concentrations only 10-20% of the
plasmids had at least one crosslinked
molecule. This low crosslinking
efficiency correlated with a slight loss of
gene activity. At higher DR9NP
concentrations, the plasmids carried one
to five steroid molecules per plasmid.
These still low crosslinking efficiencies
correlated with residual reporter
activities of 90% and 36%, respectively.
As discussed later (see 2.4.3.),
DR9NP enabled us to obtain the proof-
of-principle for the SMGD approach.
However, the above described results
highlighted two important drawbacks of
DR9NP. The first is its low crosslinking
efficiency, 100-fold lower than Psoralen.
The second one is that it can be
crosslinked only randomly on a plasmid,
interfering with the transcriptional
activity of the encoded reporter gene.
Higher and better positioned steroid
decorations should be obtained with
alternative steroid derivatives and
strategies. Some of these are described in
Figure 6. Among these, particular
attractive is the idea to use Peptide
Nucleic Acid (PNA) molecules as
carriers for steroids (see strategy e) in
Figure 6). As a matter of fact, PNA has
been already used to decorate plasmids
with NLS peptides (see 2.2.3.).
2.4.2. Three important experimental
"revolutions"
As previously discussed (see 2.3.6.), the
first steroid-DNA complexes were
obtained by mixing a few micrograms of
plasmid DNA with picomoles of Cl-21-
Et. In contrast, the crosslinking reaction
of plasmid DNA with DR9NP (see
2.4.1.) generally required nanomoles of
steroid derivative, that is 1000-fold more
hormone starting material! Since the
DR9NP synthesis was time-consuming
and its yield was limited to a few
milligrams, we had to dramatically
reduce the investment of DR9NP-
crosslinked DNA. For this purpose we
switched to a more convenient and
efficient transfection procedure, that is
lipofection in smaller wells. Thanks to
this first "revolution", we were able to
transfect genetic material in the
nanograms-range.
To test whether GR would be the
real cause of any "enhancement of
transfection" mediated by DR9NP-
crosslinked reporters, we had to develop
an experimental system in which cells
could be externally supplemented with
GR. For parallel purposes one of the
team collegues in Fribourg63, designed
special adenoviral vectors encoding GR
(see Figure 2 B of Paper 1 in 3.1.). These
adenoviruses allowed us to overexpress
GR in receptor-negative cells. Thanks to
this second "revolution", we
significantly increased the probability
for steroid-decorated plasmids to interact
with nuclear receptors.
Thanks to the DNA-crosslinking
propriety of DR9NP, we were able to
explore more deeply the observed
"enhancements of transfection". In
particular, an internal control was added
in each experiment which aimed to
measure the gene activity of steroid-
decorated reporters. This internal control
consisted in the addition of a naked
plasmid encoding a second reporter
gene, in the transfection cocktails (see
3.1.). Thanks to this third "revolution",
we were always able to normalize the
readout of  the gene activity values.
2.4.3. The proof-of-principle
My major contribution is, with no doubt,
to have obtained the necessary results to
demonstrate the feasability of the SMGD
approach. In other words, I demonstrated
for the first time, that nuclear receptors
can be exploited as gene transfer
vehicles. This proof-of-principle is
                                                          
63Dr. Stefano Brenz Verca, Group Prof. Rusconi
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extensively described in Paper 1 (see
3.1.). Within this work, I explored the
possibility of covalently attaching
steroids to DNA. In particular, I tested
the SMGD strategy with the bifunctional
steroid derivative DR9NP. My major
achievement was to demonstrate that the
expression and the nuclear accumulation
of of steroid-decorated reporter plasmids
are comparably enhanced in presence of
GR. In this context, if we compare my
results with the achievements obtained
with the NLS-coupled transgenes (see
2.2.3.3.), we will notice that my work is
the first that shows a clear correlation
between increased gene expression an
facilitated gene delivery (see Table 2). In
fact, the 3-fold higher levels of nuclear
accumulation are consistent with the 2-
to 3-fold enhancement of expression.
This correlation could be interpreted as a
facilitated nuclear transport of steroid-
decorated plasmids which results in an
equivalent enhancement of expression.
An extensive comparison between
the SMGD and the NLS-mediated gene
transfer will be extensively discussed in
Paper 1 (see 3.1.). However, further
important aspects will be mentioned
below.
It isn't so clear whether the number
of targeting signals per decorated
transgene is generally relevant for its
facilitated nuclear delivery. Branden and
co-workers observed an enhancement of
expression in presence of 11 NLS per
plasmid. However, in presence of 5 NLS
per transgene, no effect has been
observed. In contrast, Zanta and co-
workers observed a great enhancement
of expression in presence of only one
NLS, placed at the very end of the
reporter gene. Zanta's decorated
transgene had a size of 3.5 kb and was
linear. It is likely that the size and the
topology of the decorated transgene may
play an important role in determing its
nuclear import efficiency. In addition,
the position of the targeting signals on
the transgene could directly influence
both its gene activity and its nuclear
transport. The DNA molecule I used had
a size of 10kb and was circular.
According to the above hypothesis,
shorter and linear steroid-decorated
DNA fragments could be transfered with
greater efficiency in nuclear-receptor
positive cells. In this context, ideal
candidates would be synthetic
oligonucleotide such as antisense
mRNAs and chimeraplasts. To date, an
important drawback of these molecules
is indeed their impossibility to be
targeted to the nucleus of a particular
cell type. To solve this problem, special
steroid derivatives could be conjugated
to oligonucleotides. In conclusion, the
SMGD approach has the great potential
to improve efficiency and specificity of
both large and small therapeutic nucleic
acids.
2.4.4. Detection of plasmid DNA in the
nucleus of intact cells
Only a few research teams explored the
nuclear accumulation potential of NLS-
coupled DNA (see Table 2 in 2.4.3.).
This type of study has been mostly
performed using an in vitro nuclear
transport system involving digitonin-
permeabilzed cells. In this system,
cytoplasms are emptied by
permeabilization of cells membranes
with digitonin (cells are "digitonized").
The cells are subsequently supplemented
with cellular extracts containing factors
of the nuclear import machinery. Using
this system, Sebastyen and co-workers
were able to observe nuclear
accumulation of NLS-coupled DNA
fragments. However, no nuclear
accumulation has been observed by
introducing the same NLS-decorated
DNA by cytoplasmic microinjection or
transfection of intact cells. An important
difference between the in vitro model
and an intact cell is the presence of the
unalterated, full cytoplasmic content of
- 31 -
the latter. It is possible that digitonin
disrupts the cytoskeleton or other
cellular structures which are responsible
for the cytosolic sequestration of NLS-
decorated DNA in intact cells.
We could not use digitonized cells
to test the nuclear accumulation potential
of the steroid-decorated DNA. To use
this system, we had to supplement
digitonized cells with a high number of
functional GR, which is almost
impossible to maintain in vitro.
Therefore, the most straightforward
experiment has been performed, that is
compare and quantify the cellular
localization of naked and steroid-
decorated plasmids under the conditions
used for the expression studies (see
Table 1 and Figure 5 of Paper 1 in
chapter 3.1.). To this purpose, plasmids
were Rhodamine-labeled, lipofected and
analyzed by confocal microscopy.
Rhodamine-labeled vectors appeared
like punctuate red signals. As expected,
the majority of the signals localized in
the cytoplasm. However, already in the
negative controls (absence of GR and/or
absence of steroid decorations) 3 to 5 per
cent of the cells had nuclear localized
signals. I was very happy to notice that
in presence of GR, steroid-decorated
DNA mediated 3-fold higher levels of
nuclear signals than naked DNA. As
already discussed (see 2.4.3.), this result
allowed us to obtain the SMGD's proof-
of-principle, since the increase of
nuclear accumulation correlated with a
comparable enhancement of expression.
Conflicting reports appeared about
the possibility to detect nuclear localized
plasmids in living cells. The fact that
some of my confocal images were
projections of forty different optical
sections, allowed me to analyse the
observed nuclear signals by three-
dimensional viewing (see Figure 6 of
Paper in chapter 3.1.). By analysing
three different projections of apparent
nuclear signals, I was able to distinguish
signals that really localized in the
nucleus (signals within the nucleus in all
three projections) from signals that
overlapped with, but actually were not in
the nucleus (signals out of the nucleus in
at least one projection). This observation
showed that the strict two-dimensional
analysis (one projection only) of nuclear
signals can give rise to ambigous cellular
localizations. On the other hand, the
same observation confirmed that
transfected plasmid DNA can be
localized in the nucleus of living cells.
2.4.5. How could SMGD influence
human gene therapy?
The SMGD approach has been designed
to improve both the efficiency and the
specificity of nonviral vectors. We
demonstrated that the transfection
efficiency of steroid-decorated
transgenes is increased by a factor three
in nuclear receptor-positive cells (see
2.4.3.). This improvement was sufficient
to demonstrate the feasability of the
SMGD strategy (proof-of-principle), but
would probably be too low to offer a
selective advantage for the therapeutical
treatment of cells that express a specific
steroid receptor. On the other hand, we
have to consider that the selectively
enhanced gene transfer has been
obtained with poorly decorated-
transgenes (only 1 to 5 steroid molecules
for the decoration of a  10 kb plasmid
with a molecular weight of 7
megadaltons!). Furthermore, the adopted
decoration-strategy partially disabled the
transcriptional activity of the encoded
reporter gene (see 2.4.1.). Moreover, it is
likely that the steroid derivatives had a
lower binding affinity for the GR, once
crosslinked to DNA. The synthesis of
steroid derivatives with longer chemical
spacers could partially solve this
problem. From this point of view, our
achievements have to be considered not
only satisfactory, but even heroical!
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The nuclear transfer of DNA is
particularly limited in somatic cells,
mostly because these cells are non-
proliferating. As previously discussed
(see 2.2.3.) an increased nuclear
targeting could dramatically improve the
gene transfer efficiency in this type of
cells. This hypothesis has been already
confirmed using NLS-coupled
transgenes. In fact, by coupling a
reporter plasmid to a NLS-containing
peptide dimer (M9-ScT), Subramanian
and co-workers obtained a 63-fold
enhancement of expression in confluent
endothelial cells64. Similar experiments
perfomed in cycling cells mediated then
times smaller values (see Table 2 in
2.4.3.). Analogously, we aim to test the
SMGD in mitotically arrested cells,
expecting a greater effect.
We clearly showed the specificity
of the SMGD, since the enhancements of
expression were observed only in
nuclear receptor-positive cells. In this
context, the most thinkable targets could
be the steroid receptors preferentially
expressed in some type of tumours. A
concrete example is represented by the
Androgen Receptors which are
expressed at increased levels in
advanced hormone independent prostate
cancer. Prostate cancer is one of the
most diagnosed cancer forms in males.
No effective therapy exists for advanced
or metastatic prostate cancer. In fact,
chemotherapy is ineffective and
androgen ablation is pallative and non-
curative. Analogously, the Estrogen
Receptor and the Progesterone Receptor
could be targeted in breast cancer cells.
Several potential therapeutical strategies
are thinkable, including selective transfer
of tumor suppressor genes or metastatis
suppressor genes, shutdown of
oncogenes and genetic induction of
                                                          
64 Subramanian et al., Nuclear targeting peptide
scaffolds for lipofection of nondividing cells,
Nature Biotechnology, 17, 873-877 (1999)
apoptosis65. Similarly, it may be also
possible to target therapeutic
oligonucleotides, such as antisense
mRNAs, triple helix and chimeraplasts
to a particular cell population. As a
matter of fact, a recent report described
the successful targeting of androgen
receptor-positive prostatic carcinoma
cells via special designed PNA-
dihydrotestosterone conjugates66. By
designing the PNA complementary to
the c-myc oncogene, the authors were
able to target the c-myc mRNAs and
therefore decrease the cellular levels of
the MYC protein.
In conclusion, the most concrete
application of the SMGD strategy in
humans will very likely be the selective
treatment of tumours that express a
particular steroid receptors. The potential
is enormous, since candidates are the
prostate cancer and the breast cancer,
two of the world wide most diagnosed
tumoural forms. To this purpose, the
SMGD principle has to be first extended
to other nuclear receptors and tested in
vivo. The molecules that will first find a
clinical application will probably be
steroid-conjugated therapeutic
oligonucleotides. An application of
larger therapeutic nucleic acids is only
thinkable when improved steroid-
decorated transgenes will be designed in
order to achieve significatively higher
levels of preferential expression. In this
case, some steroid derivatives could also
find a niche as transfection reagents for
hardly transfectable cell lines (e.g.,
primary cells) that express a particular
steroid receptor. The SMGD could also
be combined with other nuclear targeting
strategies, such as the NLS-mediated
                                                          
65 For a recent review see: J.C. Reed, Apoptosis
as a goal of cancer gene therapy, book chapter in
The development of human gene therapy, Cold
Spring Harbor Laboratory Press (1999)
66 Boffa et al., Dihydrotestosterone as a selective
cellular/nuclear localization vector for anti-gene
peptide nucleic acid in prostatic carcinoma cells.,
Cancer Research, 60, 2258-62 (2000)
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gene transfer (see 2.2.3.3.). Which
efficacy and specificity  would a
transgene have, if decorated with both
steroids and NLS peptides? We could
also imagine combined decorations of
steroids with cellular targeting ligands,
such as the asialoglycoproteins (ASGP;
see 2.2.1.6.). How efficient would such a
decorated-transgene be expressed in
cells that express high levels of both the
ASGP receptor and GR, such as
hepatocytes? A thinkable in vivo
application, could be the combination of
SMGD with nanospheres (see 2.2.1.8.).
Would the steroid-decoration of
encapsulated transgenes improve the
transfection efficiency of nanospheres in
certain cells? Would it be possible to
externally decorate nanospheres with
steroids? Would it be feasable to
specifically target particular tissue types
with such steroid-decorated
nanospheres?
With some immagination, several
combinations of SMGD with other gene
transfer technologies are thinkable.
Some of these will probably exist one
day, enabling nonviral vectors to achieve
efficacies and specificities that can be
currently obtained with viral vectors
only.
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DNA size
and form
Targeting signals
per reporter
Enhancement
of expression
Increased nuclear
accumulation
Reference
(year)
10 kb,
linear
200 NLS NO only in
digitonized cells
Sebastyen
(1998)
3.5 kb,
linear
1 NLS 10- to 1000-fold N.D. Zanta
(1999)
10 kb,
circular
11 NLS 3- to 8-fold N.D. Branden
(1999)
10 kb,
circular
1 to 5 steroids 2- to 3-fold 3-fold in
living cells
Ceppi
(2001)
Table 2. Summary and comparison of the results obtained with steroid-decorated
and NLS-coupled transgenes.
(See 2.2.3.3. for the reported literature references)
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FIGURE 1. The "perfect" gene transfer vector doesn't exist yet …
(author of the drawing: Anne Genilloud, member of the "Ruscolab", 1997)
Conceptually, gene therapy treatments seem to be achievable quite easily. In practice,
considerable obstacles have emerged, mostly caused by the inefficacy of current gene
transfer systems (vectors). The drawing shows a crying curvilinear lady (left). Her
unhappiness is due to the fact that the taxicab (center) that has to bring her downtown
(right) does not really look safe. The taxi is even broken. With some phantasy we could
imagine that the curvilinear lady represents DNA, the broken cab represents one of the
current imperfect vector and the city represents a cell nucleus. The bottomline of this
drawing is that the nucleus is generally a problematic destination to reach for DNA,
especially if in combination with nonviral vectors.
Symbols: crying sexy lady, DNA; broken cab, vector; fence; cell membrane; city
surrounded by a thick wall; nucleus with nuclear envelope. Various cell organelles are
also schematized inside the fence.
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FIGURE 2. The principle of Steroid Mediated Gene Delivery (SMGD)
Steroid Nuclear Receptors (NRs) are cellular proteins that are continously shuttling
between the cytoplasm and the nucleus. In absence of any ligands (steroids) the NRs are
mainly localized in the cytoplasm, whereas in presence of ligands the receptors
translocate into the nucleus. A question that arises is whether the shuttling property of
NRs could be exploited to enhance the cytoplasmic-nuclear transport of DNA, very
inefficient in current nonviral vectors. The idea of the SMGD gene transfer technology is
indeed to steroid-decorate reporter or therapeutic DNA thanks to special developed
bifunctional steroid derivatives (see Figure 3).  The steroid derivatives bind to plasmid
DNA, either by ionic interaction or via an intercalating or a crosslinking reagent. The
resulting steroid-decorated plasmids are transported into the cytoplasm by conventional
transfection procedures (1). Cytoplasmically located nuclear receptors bind the steroid
moiety of steroid-decorated plasmids (2). The steroid recognition results in nuclear
translocation of the whole complex (3). Abbreviations: PM, Plasma Membrane; NR,
Nuclear Receptor; C, Cytoplasm; NE, Nuclear Envelope; NPC, Nuclear Pore Complex;
N, Nucleus.
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A: Steroid molecule
- chemical position for derivatization
- steroid hormone type
- maintanance of affinity for receptor
- nuclear translocation inducer
B: Chemical spacer
- length
- stability
- solubility
- chemical reactivity
C: DNA-interacting compound
- ionic interaction molecule
- intercalating agent
- crosslinking reagent
- incorporating molecule
FIGURE 3. A typical bifunctional steroid derivative and variables for the steroid-
decoration of plasmid DNA
All the developed bifunctional steroid derivatives are composed of a steroid molecule (A)
linked via a chemical spacer (B) to a DNA-interacting compound (C). For each of these
components there were many variables, that we explored in designing different steroid
derivatives. A list containing the names and the properties of the synthesized and
characterized compounds is reported in the Appendix. Because of its superior affinity to
the Glucocorticoid Receptor (GR) if compared to other steroids like Cortisol, almost all
compounds contained the synthetic hormone Dexamethasone. The tested chemical
spacers had a length that varied from 6 to 23 residues and had different compositions and
solubility properties.Three different DNA binders were tested: a) the intercalating agent
EtBr, b) the ionic interacting compound Spermine and c) the crosslinking reagent
Psoralen. The compounds had quite different binding affinities for GR. Out of the initial
pool of steroid derivatives, we selected the Dexamethasone-Psoralen conjugate DR9NP
(see Figure 1B in chapter 3.1), because of its superior affinity for GR and because of the
possibility to covalently link the molecule to DNA.
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FIGURE 4. Possible chemical positions for steroid derivatization
Two positions were taken into account for linking the chemical spacer to the steroid
backbone (see Figure 3); position 4 and position 21. The former was compatible with the
early proposed model for the ligand-binding interaction of the Glucocorticoid Receptor
with its strong binding ligand Dexamethasone (see text for details and literature
references) . Only in a later phase of the SMGD project, this model resulted to be wrong
inducing us to give up the idea of derivatizing position 4. In contrast, the intention of
derivatizing position 21 was consistent with the later resolved Ligand Binding Domain's
crystal structures of  the Estrogen Receptor and the Progesteron Receptor. In these
structures, the positioning of the ligand was turned by 180° with respect to the model
previously proposed. Consequently, all the steroids were chemically derivatized at
position 21.
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FIGURE 5. Expression levels of transfected reporter plasmid in GR-positive cells
under various conditions
5 µg of the CMVLacZ reporter plasmid were pre-incubated for 10 minutes at RT with 0.1
nmoles (final concentration: 10-8M), 1 nmoles (10-7M) or 10 nmoles (10-6M) of the
steroid derivative Cortisol-21-Ethidium (Cl-21-Et) or to its chemical precursors Cortisol-
21-Hemisuccinate and Ethidium Bromide (negative control). With these mixtures
proliferating GR-positive rat 3Y1 cells were transfected using the Calcium Phosphate
gene transfer procedure. The transfection efficiencies of complexed and uncomplexed
reporter DNA were compared by analysing their LacZ activities 48 hours after
transfection. Cl-21-Et-complexed reporter mediated until 4-fold higher expression levels
if compared to uncomplexed DNA or the negative controls. Similar enhancements of
transfection were observed also in another GR-encoding cell line (human A549-1) and
were absent in GR-negative cells (monkey CV-1).
Symbols: empty bar, uncomplexed plasmid; filled bar, Cl-21-Et-complexed plasmid;
hatched bar, plasmid mixed to the chemical precursors of Cl-21-Et.
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FIGURE 6. Strategies to steroid-decorate therapeutic or reporter DNA
a) In the simplest approach, the Steroid Derivative (SD) is directly crosslinked to the
reporter gene. The disadvantage is that in a fraction of plasmids, the reporter function will
be impaired. b) To preserve the reporter integrity, the SD is separately crosslinked to a
ligatable DNA fragment. c) Instead of a restriction fragment, a specially engineered
oligonucleotide can be designed to be first loadable with SD and then ligated to the
transgene. d) In this system, the SD is crosslinked to a separate DNA fragment or plasmid.
The decorated fragment is tethered to the transgene via a bifunctional triple-helix forming
oligonucleotide, which recognizes two distinct regions. In the ideal situation, we envisage
the use of PNA instead of conventional nucleic acids to drive the linking reaction. e)
Ultimately, the steroid could also be directly chemically linked to the PNA moiety.
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Abstract
Aiming at improving both the efficiency and the specificity of nonviral gene transfer, we
designed the Steroid Mediated Gene Delivery (SMGD) approach. The idea behind the
SMGD strategy is to facilitate the nuclear uptake of transfected DNA with the help of
nuclear receptors, which are natural shuttles for steroid molecules. We modelled the
SMGD with the Glucocorticoid Receptor (GR) system. The essential step was to
chemically derivatize steroids to allow their covalent linkage to plasmid DNA while
maintaining their availability for the GR. To this purpose, we synthesized and tested a
large number of bifunctional steroid derivatives and selected the compound that we
shortly denominate DR9NP for the experiments presented in this work. We show that GR
efficiently translocates into the nucleus upon exposure to few nanomolar amounts of
DR9NP. Furthermore, the expression of DR9NP-decorated reporter plasmids was
reproducibly enhanced 2- to 3-fold in presence of GR. The effect was occurring only in
cells expressing the GR, was independent from the transactivation potential of GR and
correlated with an equivalent plasmid nuclear accumulation. The final general aim of the
SMGD approach is to offer an additional  selective advantage to the gene transfer-based
treatment of somatic tissues that express a specific steroid receptor.
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Introduction
Nonviral gene therapy vectors are generally designed to allow the genetic material to
cross the cell membrane of mammalian cells with high efficiency. However, only a small
portion of the delivered nucleic acids undergoes nuclear translocation. The nuclear
envelope has been identified to be a major barrier for the gene transfer of foreign DNA
(1-3), specially in non-dividing cells (4). Among the most promising strategies that have
been proposed to overcome this barrier we shall mention the linkage of the SV40 nuclear
localization signal (NLS) to reporter DNA (5-7). Other obstacles to nuclear accumulation
of plasmid DNA include the entrapment of DNA in the endolysosomal compartment (8)
and the degradation of DNA by cytosolic nucleases (9). Viruses have evolved
sophisticated molecular mechanisms for the nuclear delivery of their genes (reviewed by
Whittaker et al. (10)), a feature that explains in part the higher transduction efficiency of
viral vectors. Another factor limiting the efficacy of nonviral vectors is the inability to
specifically target genes to a desired cell type. Most targeting techniques developed to
date enable DNA to be internalised into the cytoplasm of the desired cells via specific
surface ligand docking (11). A step which has been rather neglected until recently is the
possibility to preferentially favour the transfer therapeutic genes into the nucleus of
particular cell types, independently of the DNA delivery method.
In order to improve both the efficiency and the specificity of nonviral gene transfer,
we designed the Steroid Mediated Gene Delivery (SMGD) approach that is illustrated in
Fig. 1A. The rationale behind SMGD is to improve the nuclear uptake of transfected
DNA with the help of nuclear receptors, which are natural shuttles for steroid molecules.
Nuclear receptors such as the glucocorticoid receptor translocate to the nucleus once
activated by incoming steroids (12). The basic strategy is to chemically derivatize
steroids and to link them covalently to plasmid DNA. The resulting steroid-decorated
plasmids are first introduced in the cell by conventional transfection procedures (Fig. 1A,
point 1). Cytoplasmically located nuclear receptors are then expected to bind the steroid
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moiety of steroid-decorated plasmids (Fig. 1A, point 2), resulting ultimately in nuclear
translocation of the complex (Fig. 1A, point 3). Our approach is analogous to the recently
reported nuclear import strategy of the HIV-1 genome (13). In that report, the authors
suggested that the pre-integration complex central DNA flap interacts with cellular or
viral proteins that shuttle between the cytoplasm and the nucleus of the host cell.
According to this model, this interaction would enable the linear HIV-1 genome to be
crawled through the nuclear pore.
In the present study, we modelled the SMGD approach with the well characterized
Glucocorticoid Receptor (GR) system (14, 15). To this purpose we synthesized and tested
several bifunctional steroid derivatives, all composed by a steroid molecule covalently
linked to a DNA interacting compound (Bernasconi et al., in preparation). The aim of this
work was to test the feasibility of the SMGD using the steroid derivative DR9NP (Fig.
1B), which comprises a dexamethasone moiety and a psoralen function and has been
selected from our initial collection of synthesized hormone derivatives (Rebuffat et al., in
preparation) . Our work unequivocally demonstrates that the expression and the nuclear
uptake of DR9NP-decorated reporter plasmids are selectively enhanced in presence of
GR. This study is the first that shows that nuclear receptors can be exploited as gene
transfer vehicles.
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Results
Synthesis of the steroid derivative DR9NP. The steroid hormone Dexamethasone (Dex)
was conjugated to the DNA-crosslinking molecule Psoralen (Aminotrioxsalen) via a 9
atoms long spacer. The resulting steroid derivative was named for simplicity DR9NP to
outline its 9 atoms-long spacer, the dexamethasone and the psoralen moieties and the
urethane bonds (Fig. 1B). DR9NP (patent pending) has the characteristic to contain two
urethane bonds (OCONH) which link the spacer to the two polycyclic structures. The
stability of the urethane bonds has been verified under acidic (pH 5) and alkaline (pH 9)
conditions, by proteinase K (pH 7.8, 50 µg/ml) and dispase (2.4 U/ml) digestion and after
incubation with cellular extracts and with DMEM / 10% FCS (Bernasconi et al., in
preparation). All the tests indicated that DR9NP is stable under typical cell culture
conditions.
Similar bifunctional steroid derivatives were synthesized, differing from DR9NP in
the spacer length and composition, but DR9NP has been selected from this initial
collection of hormone, because of its excellent solubility in various solvents and its
superior affinity for GR (Rebuffat et al., in preparation).
DR9NP induces nuclear translocation of GR. GR(Ala) is a previously
characterized dominant negative mutant of the glucocorticoid Receptor (GR) (16).
GR(Ala) maintains competence for hormone binding, nuclear translocation and DNA
binding, but is incapable for transactivation (16). We previously observed a more
pronounced cytoplasmic localization of GR(Ala) than GR in absence of steroid hormones
(16), making GR(Ala) an ideal candidate to test the nuclear translocation potential of
steroids. For this purpose we generated the chimeric protein GR(Ala)GFP (Fig. 2A,
construct 1). The cellular localization of GR(Ala)GFP was analyzed in presence or in
absence of DR9NP. HeLa cells were transiently transfected with GR(Ala)GFP, fixed with
formaldehyde/glutaraldehyde and inspected by fluorescence microscopy in the presence
of UV-light. In absence of hormones GR(Ala)GFP was mainly localised in the cytoplasm
(Fig. 1C), whereas in the presence of Dex (Fig. 1D) or DR9NP (Fig. 1E) the chimeric
- 47 -
protein was localised in the nucleus indicating that the two steroids have a similar binding
affinity for the Glucocorticoid Receptor. In vitro binding studies revealed indeed
dissociating constants (KD) of 5x10
-8 M for DR9NP and 10-9 M for Dex (Rebuffat et al.,
in preparation).
DR9NP can be crosslinked to plasmid DNA. Psoralen is a photo reactive
molecule which can be crosslinked to DNA upon long-wave (365 nm) UV irradiation
(reviewed by Hearst et al.(17)). Under those conditions, DNA is typically reacted with 1
Psoralen molecule per 100 base pairs (17). We first tested by NMR analysis whether
DR9NP is still intact after UV-irradiation and we found no difference between the NMR
profiles before and after UV-irradiation (Bernasconi et al., in preparation). To test
whether DR9NP can be crosslinked to DNA, the plasmid CMVLacZ (Fig. 2A, construct
2) was UV-irradiated in absence and at four different DR9NP concentrations (0 M, 10-8
M, 10-7 M, 10-6 M and 10-5 M). After irradiation, unreacted DR9NP molecules were
removed by Chloroform/ Isoamyl alcohol extraction. The resulting DR9NP-crosslinked
CMVlacZ preparations (D8, D7, D6 and D5) and the negative control D0 were linearized
by restriction enzyme digestion, alkali-denatured and analyzed by gel electrophoresis
(Fig. 3A). Under these conditions, crosslinked DNA fragments remain double stranded
and are visible as slow-migrating bands (dsDNA), whereas uncrosslinked DNA
fragments become single stranded and are visible as fast-migrating bands (ssDNA). As
expected D0 yields exclusively ssDNA (lane 1), while D8, D7 and D6 produce increasing
amounts of dsDNA (lanes 2,3 and 4). The preparation D5 remains essentially double
stranded (lane 5). The percentage of crosslinked DNA has been calculated for each vector
preparation (empty circles in Fig. 3B and Experimental Procedures). Only 10% of D8
vectors and 20% D7 vectors have at least one crosslink. In contrast 90% of D6 vectors
have at least one crosslink and D5 vectors have an average of five crosslinked DR9NP
molecules. A 100-fold higher crosslinking efficiency was obtained with native Psoralen
(data not shown).
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The reporter gene activity of each preparation has been determined by measuring
the amount of beta-Galactosidase (ß-Gal) in CV-1 cells transiently transfected with equal
amounts of the corresponding DNA (filled circles in Fig. 3B). When 6% (D8), 13% (D7),
58% (D6) of the plasmids are crosslinked, there is only a moderate loss of reporter gene
activity. In contrast when 99% (D5) of the plasmids are crosslinked, the gene activity is
reduced to 36%. The loss of gene activity is likely due to the fact that a portion of the
reacting DR9NP molecules crosslinks the reporter within the biological active regions
(Fig. 3C).
The beta-Galactosidase expression of DR9NP-crosslinked CMVlacZ is
enhanced in presence of GR. To test whether GR would affect the transfection
efficiency of DR9NP-crosslinked CMVLacZ we first had to develop an experimental
system in which cells could be externally supplemented with GR. For this purpose we
generated two adenoviral transfer vectors, one encoding for wild type GR (AdGR,
construct 5 in Fig. 2B) and one encoding for the mutant GR(Ala) (AdGR(Ala), construct
6 in Fig. 2B). CV-1 cells were chosen as targets for infection , as this cell line does not
express GR endogenously (18, 19). By infecting CV-1 cells with an adenovirus encoding
GFP (AdGFP, construct 7 in Fig. 2B)  at a multiple of infectivity (MOI) of 3, 100% of the
cells expressed the reporter gene, indicating that CV-1 cells can be infected efficiently by
adenoviruses (our unpublished data).
 In a first experiment, CV-1 cells were first infected with AdGFP (Mock) or AdGR
and subsequently lipofected either with D0 or D6. To enable full expression of the
adenovirus encoded GR, cells were transfected 19 hours after the infection (see Fig. 4A
for time course). Uncrosslinked CMVLuc was added to each transfection cocktail for
readout normalisation. Cells were harvested and the activities of ß-Gal and Luc were
determined simultaneously. The normalized expression levels are shown in Fig. 4B. In
absence of GR there is no difference in the expression levels from the D0 and D6
preparations (compare bars 1 and 2), whereas in presence of GR, D6 mediates 2-to 3-fold
higher ß-Gal expression than D0 (compare bars 3 and 4). An analogous experiment has
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been performed by comparing the expression levels of D0 and D5 (Fig. 4D). In absence
of GR, the activity of D5 is reduced to 40% compared to D0 (compare bars 7 and 8)
confirming the loss of gene activity observed previously (Fig. 3B). In presence of GR, D0
and D5 have similar expression levels (compare bars 9 and 10), meaning that also D5 is
subject to a  2-fold to 3-fold enhancement of expression (compare bars 8 and 10). No
significant enhancements of expression were observed with the vector preparations D8
and D7 where only a minority of the molecules bears a crosslinked steroid (data not
shown). Comparable enhancements of expression were reproducibly obtained in a cell
line which express GR endogenously (human lung carcinoma cells A549-1, data not
shown), indicating that a DR9NP-mediated increased transfection efficiency can be
obtained also at physiological concentrations of GR.
To explore whether the transactivation potential of GR rather than its nuclear
translocation is responsible for the observed enhancement of expression, the reporter
gene activity of the different vector preparations was analyzed in presence of GR(Ala)
(Fig. 4D). As discussed previously, this mutant GR is incapable of sustaining
transactivation. We found that, similar to GR, GR(Ala) enables D6 to express higher ß-
Gal levels than D0 (compare bars 5 and 6) and rescues D5  to display expression levels
comparable to D0 (compare bars 11 and 12). This observation renders unlikely the
possibility that the observed enhancement of expression is caused by an increased
transcriptional activity of the DR9NP-crosslinked vectors and reinforces the
interpretation that the effect is caused by a facilitated nuclear delivery.
Enhanced expression of DR9NP-crosslinked CMVlacZ correlates with increased
plasmid nuclear accumulation. To follow the cellular localization of the vectors, CV-1
cells previously infected with AdLacZ (Mock), AdGR or AdGR(Ala), were lipofected
with Rhodamine-labeled D0 or D5 and imaged with a confocal laser scanning
microscope. A representative picture of a central optical section of transfected cells is
shown in Fig. 5A where Rhodamine-labeled aggregates appear like punctuate white
signals. The majority of the signals is localised in the cytoplasm or in the perinuclear
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region of the cells and only few signals are localised in the nuclei (arrows in Fig. 5A).
The cellular localization of the signals was quantified for each condition by averaging the
scored localization of signals in many cells for each experimental condition (see legend to
Fig. 5 and Experimental Procedures). The details of all the counted signals and the
percentages of cytoplasmic, perinuclear and nuclear signals are reported in Table 1. In the
mock-infected cells there is no significant difference in the cellular localization of D0 and
D5 (compare columns B and D).  In presence of GR, the D5 preparation produces a 3-
fold higher percentage of nuclear signals than D0 (13% in column H vs. 4% in column
F). Likewise, GR(Ala) mediates 3-fold higher levels of nuclear signals for D5 if
compared to D0 preparation (10% in column N vs. 3% in column L). In presence of GR
or GR(Ala), no significant difference is detectable in the percentage of perinuclear or
cytoplasmic signals (compare column H with column F and column N with column L).
The percentages of nuclear localized signals are graphically represented in Fig. 5B.
The 3-fold higher levels of nuclear accumulation observed for DR9NP-crosslinked
CMVlacZ in presence of GR, although modest, are consistent with  the 2-fold to 3-fold
enhancements of expression observed previously (Fig. 4). This correlation is best
interpreted as resulting from a facilitated nuclear transport of DR9NP-decorated plasmids
which results in an equivalent enhancement of expression.
Proof of nuclear localization of transfected plasmid DNA. Conflicting reports
appeared recently regarding the ability to visualise nuclear localized plasmid DNA after
transfection of cultured cells. A report described the impossibility to detect any nuclear
plasmid using different microscopic techniques, that is light microscopic evaluation of
fluorescently labeled DNA and electron microscopic evaluation of gold-labeled DNA (1).
Another report described the detection of nuclear localized fluorescent plasmids in 20% -
30% of the transfected cells (20). These contrasting results induced us to explore more
deeply our observed putative nuclear localized signals. For this experiment, CV-1 cells,
previously infected with AdGR, were lipofected with Rhodamine-labeled D5. To better
visualise cellular structures, the cells were stained with acridine orange and then imaged
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with a confocal laser scanning microscope as for the previous experiments. Images were
composite of 35 optical sections obtained at 200 nm intervals. A typical wide field image
is shown in Figure 6A where Rhodamine-labeled vectors appear as before like punctuate
red signals. From this perspective, signals are visible in the cytoplasm (open arrows), in
the perinuclear region (closed arrows) or within the nucleus (rectangle) of the cells. We
further verified the localization of the nuclear signals by tri-dimensional viewing. Fig. 6B
represents an enlarged view of the cell highlighted in Fig. 6A. A vertical portion of the
cell which includes three apparent nuclear localized signals (dashed vertical lines) has
been rotated clockwise by 90 degrees and is projected in Fig. 6C. From this perspective,
two signals are in the nucleus and one signal is in the perinuclear region. Analogously, a
horizontal portion of the cell which includes the nuclear signals (dashed horizontal lines)
has been rotated clockwise by 90 degrees and is projected in Fig. 6D. Also from this
perspective the same two signals are in the nucleus and the same single signal appears to
coincide with the perinuclear region. We collected similar observations for uncrosslinked
plasmids and also in absence of GR (data not shown) and confirmed the data presented in
Table 1 also under those more stringent conditions. These observations demonstrate that
the majority of the punctuated signals seen as overlapping with the nucleus area after
transfection of Rhodamine-labeled plasmids can be unequivocally located within the
nucleus.
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Discussion
In this work we described the Steroid Mediated Gene Delivery (SMGD) approach, a
novel technique to improve both the efficiency and the specificity of nonviral gene
transfer. In particular, we explored the possibility to exploit nuclear receptors as ferries
for plasmid DNA. Although other nuclear receptors could have been chosen, we
modelled the SMGD with the Glucocorticoid Receptor (GR) system, because the
necessary expression vectors, receptor mutants and commercial ligands for derivatisation
were available. For the experiments described here, we used the bifunctional steroid
derivative DR9NP (Fig. 1B). We first demonstrated that GR translocates into the nucleus
upon exposure to DR9NP (Fig. 1C). Secondly, we showed that DR9NP can be
crosslinked to plasmid DNA (Fig. 3A). Finally, our major achievement was to
demonstrate that the expression and the nuclear accumulation of DR9NP-decorated
reporter plasmids are comparably enhanced in presence of GR and that this is
independent of its transactivation potential (Figs. 4, 5, and 6).
Several recent reports proposed similar approaches to improve the nuclear import
of plasmid DNA. In particular, different strategies have been described to covalently link
the SV40 T-antigen nuclear localization signal (NLS) to reporter DNA. The attachment
of an NLS-bearing peptide to plasmid DNA increased nuclear accumulation of the
conjugated DNA in digitonin-permeabilised cells (5). Another report described the
preparation of an NLS-coupled linearized reporter construct (6). In that work, the authors
state a 10-fold to 1'000-fold enhancement of transfection but did not verify the effect on
actual DNA transport into the nucleus by physical methods. Recently, a correlation
between the effect of NLS on both DNAs nuclear import and expression has been
reported, reinforcing the feasibility of this approach (21). A further report described a 3-
to 8-fold enhancement of transfection obtained by conjugating plasmid DNA with a
PNA-NLS fusion (7). This result is comparable to the 2- to 3-fold enhancement of
expression observed for the pilot SMGD approach reported here (Fig. 4B). Taken
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collectively, these results suggest that linearized NLS-coupled reporters provide higher
transfection efficiency than circular NLS-coupled plasmids. It is thus possible that after
passing a certain size-threshold, linearized DNA is probably better imported into the
nucleus than circular DNA. This hypothesis is supported by some nuclear import
strategies present in nature. For instance, the genome of large DNA viruses, such as
Herpes Simplex virus and Adenovirus is transported into the nucleus of host cells as a
linear fragment coupled to different NLS-containing proteins (10). Analogously, the
Agrobacterium tumefaciens T-DNA is imported in the nucleus of plant cells as a linear
single-stranded DNA coupled to the NLS-containing proteins VirD2 and VirE2 (22). To
our knowledge, so far there has been no report describing a direct comparison between
the transfection efficiencies and nuclear import efficiency of linear versus circular NLS-
coupled reporters. This type of study is currently in progress for our steroid-decorated
reporters.
Although a promising strategy, the delivery of NLS-coupled transgenes does not
allow to target DNA specifically to a desired cell type, since the factors comprising the
import machinery interacting with NLS are apparently expressed ubiquitously (23). The
final general aim of the SMGD is indeed to offer a selective advantage to the
therapeutical gene transfer in target cells that express a specific steroid receptor. Potential
targets could be nuclear receptors present in some type of tumours or degenerating tissues
(24, 25). For example Androgen receptors could be targeted in prostate cancer (26, 27)
and Progesterone or Estrogen receptors could be targeted in breast cancer cells (28, 29).
As a therapeutical strategy, it may be possible in this way to transfer a tumour suppressor
gene or any antitumoral factor selectively to these cancer cells. Analogously, it may be
also possible to favour the accumulation of synthetic oligonucleotides such as antisense,
ribozymes, and chimeraplasts to selected cell layers and tissues. Different steroid
derivatives which could be conjugated to these molecules are under development. Other
nuclear receptors expressed in somatic cells, such as those for retinoic acids, vitamin D,
thyroid hormones, peroxysome proliferators etc., may also be targeted by an extended
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SMGD procedure. Since the nonviral gene transfer in non-dividing cells is even less
efficient (4), a greater effect of nuclear targeting is expected in this type of cell (30). We
are currently testing this hypothesis in artificially mitotically arrested cells. Obviously,
also direct DNA binding by shuttling transcription factors instead of complicated
crosslinking with ligands, can in principle be exploited to favour nuclear accumulation.
We have momentarily renounced to this type of experiments since it is arduous to prove
that the enhanced expression is indeed due to transport rather than to direct transcriptional
effects and it is also difficult to avoid unspecific binding to cryptic sites within the
constructs. For instance, a recent report described the cell-specific import of plasmid
DNA (31). In that work, a DNA element containing binding sites for the transcription
factor SRF was inserted in a reporter plasmid. The plasmid was allegedly preferentially
localized in the nucleus of SRF expressing cells. The authors also obtained a 5-fold to 10-
fold enhancement of expression, but did not explore whether the effect was caused by the
transactivation potential of SRF rather than its nuclear translocation. In addition, the
inserted DNA element contained the smooth muscle gamma actin (SMGA) promoter
which has an intrinsic transcriptional enhancer activity (32). A further report described
that the presence of the  Epstein-Barr Virus oriP sequence on a plasmid increased 100-
fold the expression of the encoded reporter gene in cells expressing EBNA1 (33). The
authors concluded that the increase of gene expression resulted from the additive effects
of plasmid nuclear import and oriP-EBNA1 transcriptional enhancement but could not
cleanly dissociate these effects. In our work we observed higher expression levels of
steroid-decorated reporters even in presence of a mutant GR which is totally unable to
transactivate (Fig. 4D). Furthermore, the 2- to 3-fold enhancement of expression
correlated with an equivalent plasmid nuclear accumulation (Fig. 5B). This correlation
suggests that the effect is caused indeed by a facilitated nuclear delivery and renders
alternative explanations rather unlikely.
In this work, we were also able to demonstrate by 3D-reconstruction of images that
transfected plasmid DNA can be localized into the nucleus of cultured cells. Formally, we
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were expecting diffused staining inside the nucleus. However, punctuated signals similar
to ours have been reported for nuclear imported plasmids in digitonin-permeabilised cells
(34) and for HIV-1 genomes in the nuclei of infected cultured cells (13). More diffuse
patterns have been found for DNaseI treated DNA, for oligonucleotides and for NLS-
bearing proteins (34). Taken together, these results suggest that the diffused nuclear
staining observed in several reports (8) may be caused by the nuclear import of degraded
nucleic acids rather than intact plasmid DNA. However, we cannot exclude that the
punctuate staining simply depends on the adopted transfection reagent (cationic lipids)
and/or the little amount (30-70 ng) transfected nucleic acids. To clarify this, we are
currently following the fate of cytoplasmically microinjected labelled DNA under the
various conditions (decorated versus native, in presence versus absence of GR etc.).
The observed punctuated signals have apparent diameters that vary from 200 to 800
nm (Fig. 6B). It has been proposed that 5 to 20 plasmids are complexed  in a single
DNA/lipid particle (35). However, from our experiments, it is not possible to determine
the number of plasmids that may generate each single signal. Since it is still not clear
whether DNA uncoating takes place preferentially in the cytoplasm or in the nucleus
(36), we cannot exclude that a fraction of the nuclear localized plasmids is still bound to
some residual cationic lipids or that it re-aggregates after internalisation.
In conclusion, this study demonstrates for the first time that a nuclear receptor can
be used as a gene delivery helper vehicle. Our work is still at the level of a proof-of-
principle and several strategies are envisageable to further improve the efficiency of the
SMGD approach. Besides trying to synthesize bifunctional derivatives that better
maintain affinity for the cognate receptor, we are aiming at a more localised decoration of
the transgene. in fact, the major drawback of our "first generation" steroid derivatives is
that they can be crosslinked only randomly on a plasmid, interfering with the
transcriptional activity of the encoded reporter gene. We are currently developing a
"second generation" of steroid derivatives which could be conjugated to biologically
inactive regions of reporter plasmids. In particular, we are exploring the possibility to use
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triple-strand forming PNA ((20) and references therein) as carrier for steroid molecules.
With this strategy we should obtain plasmids with higher and better positioned steroid-
decorations compared to DR9NP. A higher number of clustered conjugated steroids per
plasmid should increase the probability for nuclear receptors to interact with the complex.
This should in turn enhance the nuclear transport of steroid-decorated DNA. Future
studies will also elucidate whether other nuclear receptors could be exploited as ferries
for DNA. To this purpose, the "second generation" of steroids will also include ligands
for the estrogen, androgen, progesterone and mineralocorticoid receptor. These molecules
may constitute powerful tools for clinical applications aiming at the selective
macromolecular treatment of target tissues that express a specific steroid receptor.
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Experimental protocols
Construction of reporter plasmids and recombinant adenoviruses.
Reporter plasmids: The plasmid CMVGR(Ala)GFP (Fig. 2A, construct 1) was
constructed by fusing a GFP(S65T) mutant (37) C-terminally to a rat glucocorticoid
receptor (GR) bearing a frame shift mutation in its N-terminus transforming a natural
poly-glutamine stretch into a poly-alanine stretch (16). The resulting GR(Ala)GFP fusion
protein ORF is constitutively expressed under the control of the human CMV promoter
and is followed by the rabbit ß-globin splice signal and 3' polyadenylation signal and a
SV40 origin of replication. Plasmids CMVLacZ (Fig. 2A, construct 2) and MMTVLacZ
(Fig. 2A, construct 3) carry an expression cassette for ß-Galactosidase (ß-Gal) driven by
the human CMV promoter and MMTV promoter, respectively (S. Wieland and S.
Rusconi, unpublished). In both plasmids the ß-Gal ORF is followed by the rabbit ß-globin
splice signal and 3' poly-adenylation signal. Plasmid CMVLuc (Fig. 2A, construct 4; kind
gift of M. Imhof) expresses firefly luciferase (Luc) under the control of the human CMV
promoter and has an SV40 polyadenylation signal. All the plasmids were purified by
CsCl. Plasmid sequences and construction details are available on request.
Recombinant adenoviruses: All recombinant adenoviruses were generated as cloned full
length recombinant genomes (referred to as "virusmids") in E. coli (38) from a PacI
flanked, E1E3 deleted adenovirus type 5 backbone (vmRL-CMV1;  Brenz Verca, et al.,
in preparation). AdGR (Fig. 2B, construct 5) and AdGR(Ala) (Fig. 2B, construct 6) were
generated by recombining vmRL-CMV1 with the corresponding expression vectors for
wild type and Ala-mutant Glucocorticoid Receptor, respectively. To avoid toxicity
problems by expressed transcription factors, we engineered the insert into a repressible
cassette that allows silent propagation in a Tet-Repressor expressing packaging cell line
(S. Brenz Verca, in preparation). The construction of AdGFP (Fig. 2B, construct 7) from
virusmid vmRL-CMV1 is described in detail elsewhere (39). AdGFP expresses
Clontech's EGFP mutant under control of the human CMV promoter. AdLacZ (Fig. 2B,
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construct 8) was constructed on an analogous way from virusmid vmRL-CMV1. Viruses
were propagated and purified by standard methods (40). The lysates were titrated as
described elsewhere (S. Brenz Verca, in preparation) by an end-point cytopathic assay
(41, 42), aliquoted and stored at –70 °C.
Preparation of DR9NP-crosslinked DNA.
The steroid derivative DR9NP (6-{[(dexamethasone)carbonyl]amino}hexyl(2,5,9-
trimethylpsoralen)methylcarbamate; patent pending) was synthesized as described (43).
DR9NP was resuspended in Ethanol to a concentration of 10-3M. Five different
irradiation cocktails were made by mixing 100 µg CMVLacZ with 0, 0.04, 0.4, 4 or 40
nmoles DR9NP in 4.2 ml H2O. The final concentrations in the cocktails were 25 ng/ml
for DNA and 0M, 10-8M, 10-7M, 10-6M or 10-5M for DR9NP, respectively. Each
cocktail was transferred into a well of a 6-well tissue culture plate (TPP). The plate was
then covered by its lid and put on top of an ice-bed in a plastic box inside a crosslinker
apparatus (BIO-LINK, BLX) equipped with four UV lamps (type T-8.L, l=365 nm). The
cooled plate was then irradiated for 1 hour with an approximate UV-intensity of 12
J/cm2. The crosslinked products were extracted twice with Chloroform/Isoamyl alcohol
(24:1), precipitated with ethanol and resuspended in TE (10 mM Tris-HCl, 1 mM
EDTA). For characterization, the resulting DR9NP-crosslinked CMVLacZ preparations
were linearized by restriction enzyme digestion, alkali-denatured and analyzed by gel
electrophoresis.
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Cell culture, adenoviral infections, transfections and reporter assays.
Cell culture: HeLa cells and CV-1 cells were grown in DMEM (GIBCO) supplemented
with 2.5% Fetal Calf Serum 2.5% New Born Calf Serum, 1% Penicillin/Streptomycin and
1% L-Glutamine. Cells were maintained at 37 °C in a 5% CO2 100% humidified air
atmosphere.
Adenoviral infections: 100'000 CV-1 cells per well were seeded in 24-well tissue culture
plates to reach 60-80% confluence during transfection. At time point 0h (see Fig. 4A for
experimental outline), cells were incubated with DMEM (3% FCS) supplemented with
adenoviral particles to reach a Multiple Of Infectivity (MOI) of 14. At time point 15h,
cells were rinsed twice with Tris Buffered Saline (TBS).
Transfections: At time point 19h, cells were lipofected with the transfection reagent
TRANSFAST (Promega) following the manufacturer's instructions, with a DNA to
cationic lipid charge ratio of 1:2. Briefly, 0.1 µg naked or DR9NP-crosslinked CMVlacZ,
1 µg CMVLuc and 0.9 µg sonicated calf thymus DNA as carrier were covered with a
mixture containing 12 µl TRANSFAST and 2 ml serum-free medium. 200 µl of this
transfection cocktail, containing 10 ng CMVLacZ and 100 ng CMVLuc, were added to
each well. In the samples that included more than 10 ng LacZ reporter plasmid, the
amount of carrier DNA was proportionally diminished. After 1 hour, the cells were rinsed
twice with TBS and supplemented with prewarmed complete medium.
Reporter assays: At time point 48h, cells were harvested and the activities of ß-
Galactosidase (ß-Gal) and Luciferase (Luc) were determined simultaneously with the
chemiluminescent gene reporter assay Dual Light (Tropix, Perkin Elmer) following the
manufacturer's instructions. Typical measured values were between 106 and 107 RLU /
mg protein for Luc and 105-106 RLU / mg protein for ß-Gal. For normalization, the
values obtained for ß-Gal were divided by the values obtained for Luc.
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Nuclear translocation assay.
HeLa cells were trypsinized and seeded at around 20-30% confluence into small
(diameter of 5 cm) tissue culture dishes. Cells were allowed to adhere to the dish for 4-6
hours. Cells were then transfected by calcium phosphate with 5 µg CMVGR(Ala)GFP, 1
µg of an expression vector encoding for SV40 T-antigen and 4 µg of sonicated calf
thymus DNA as carrier. The precipitate was allowed to deposit on the cells for 15 hours
(37 °C, 5% CO2). The cells were then rinsed twice with TBS, supplemented with fresh
medium and further incubated under standard conditions. 48 hours after transfections,
cells were fixed with 2% Formaldehyde / 0.2% Glutaraldehyde and inspected in the
presence of UV-light, using a Zeiss Axiovert fluorescence microscope. Where mentioned,
Dexamethasone or DR9NP have been added 1 hour before fixation, to get a final steroid
concentration of 5x10-7M in the cell medium.
DNA-labeling, confocal microscopy and image analysis.
Naked and DR9NP-crosslinked CMVLacZ plasmids were labeled with Rhodamine using
the Label-It reagent (Panvera) following the manufacturer's instructions. Briefly, the
plasmid (5 µg) was diluted to a final concentration of 0.1 mg/ml, and 50 µl of the labeling
reagent were added. The labeling reaction proceeded for 1 hour at 37 °C, followed by
Microspin Column purification (Sephadex G50) to remove incorporated fluorescence.
According to the manufacturer, by using the labeling reagent to DNA ratio of 1:1 (v:w), a
labeling efficiency of one Rhodamine molecule per 20-60 base pairs should be achieved.
The overall efficiency of Rhodamine labeling was qualitatively compared by  agarose
electrophoresis in absence of EtBr. CV-1 cells cultured on slides (placed in the wells of a
24-well tissue culture plate) were lipofected with the Rhodamine-labeled vectors as
described above (see Cell culture, adenoviral infections, transfections and reporter
assays). Considering the losses during the extraction procedure, the amount of transfected
Rhodamine-labeled DNA was estimated to be between 30 and 40 ng per well. 24 hours
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after transfection, the cells were fixed with 4% Formaldehyde and examined using a BIO-
RAD 1024, argon / krypton confocal laser scanning fluorescence microscope (LSCM,
BIO-RAD Microsciences Division Ltd), with K1 and K2 dual filter blocks. To
quantitatively evaluate the cellular localization of the Rhodamine signals (see Fig. 5 and
Table 1), low magnification (x 20 objective), central optical sections of 500 nm were
taken. The original coloured pictures were converted electronically to black and white
pictures, so that Rhodamine-labeled vectors appeared like punctuate white signals (see
Fig. 5A). For the precise cellular localization of Rhodamine signals (see Fig. 6), higher
magnification (x 60 or 100 oil objective), 30 to 50 Z-series consecutive optical sections of
200 nm thickness were taken. To visualize nuclei and general cellular structures, cells
were previously stained with acridine orange. The LSCM was set to All-Lines of
Excitation of the argon / krypton laser, with acridine orange stained cells detected at 605
nm and Rhodamine signals detected at 680 nm. Each optical section was cleaned using a
3x Kalman averaging filter to improve the signal / noise ratio. The possibility of
fluorescence bleed from one fluorochrome to the other was controlled by initially
visualising individual fluorochromes in single channel mode using either a 568 nm or a
647 nm excitation filter for acridine orange or Rhodamine, respectively. Collected z-
series optical sections were superimposed using the Laser-Sharp-Processing software
(BIO-RAD) to enable the reconstructed three-dimensional relationships to be visualised
as two-dimensional photomicrographs. Confocal optical sections were also imported into
the image analysis software Imaris (Bitplane AG, CH), where cut planes of the confocal
images were viewed in both the x  and y axis to determine the precise localization of the
signals. No filters or image correction were applied to the images.
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Figure 1. The principle of SMGD and structure and properties of the bifunctional
steroid derivative DR9NP. (A) Schematic representation of the cellular events involved
in SMGD. Several DR9NP molecules are crosslinked to plasmid DNA (pDNA). The
resulting complex DR9NP-pDNA is transported into the cytoplasm by conventional
transfection (1). Cytoplasmically located GR binds to the steroid moiety of DR9NP-
pDNA (2). Steroid recognition results in nuclear translocation of GR and associated
DR9NP-pDNA (3). Abbreviations: PM, Plasma Membrane; GR, Glucocorticoid
Receptor; C, Cytoplasm; NE, Nuclear Envelope; NPC, Nuclear Pore Complex; N,
Nucleus. (B) DR9NP (see Experimental Procedures for extended nomenclature) is
composed by the steroid hormone Dexamethasone (fluorinated polycyclic structure at the
left) linked via urethane linkage to a 9 atoms long spacer to the DNA-crosslinking
molecule Psoralen (polycyclic structure at the right). (C,D,E) Cellular localization of
transiently transfected GR(Ala)GFP in absence of hormone (C), in presence of either
5x10-7 M Dexamethasone (D) or 5x10-7 M DR9NP (E). Scale bar: 50 µm.
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Figure 2. Utilised plasmids and recombinant adenoviruses. (A) Reporter plasmids.
The linear maps outline the essential biological elements but are drawn out of scale.
Vector names: 1, CMVGR(Ala)GFP; 2, CMVLacZ; 3, MMTVLacZ; 4, CMVLuc. (B)
Recombinant adenoviruses. The genome of the recombinant Ad5 is schematised out of
scale. Vector names: 5, AdGR; 6, AdGR(Ala); 7, AdGFP; 8, AdLacZ. Symbols and
abbreviations: wavy line, plasmid sequence; T7, T7 bacteriophage RNA polymerase
promoter; CMV, Cytomegalovirus promoter/enhancer; bent arrow, transcription start;
hatched box, poly-alanine stretch; GR(Ala)GFP, fusion of GR(Ala) and GFP; broken
line, rabbit beta-globin splice signal; empty circle, rabbit beta-globin 3' polyadenylation
signal; hatched oval, SV40 origin of replication; LacZ, Beta-Galactosidase gene; MMTV,
Mouse Mammary Tumour Virus inducible promoter; Luc, Luciferase gene; hatched
circle, SV40 polyadenylation signal; filled box, adenoviral inverted terminal repeat
(ITR); ∆E1, deletion of adenoviral E1 region; ∆E3, deletion of adenoviral E3 region;
filled circles, 2x tet-operators; GR, Glucocorticoid Receptor gene; GR(Ala), GR
dominant negative mutant (16); GFP, Green Fluorescent Protein gene.
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Figure 3. Structural and functional characterization of DR9NP-crosslinked
CMVLacZ. (A) 1% Agarose gel electrophoresis of linearized alkali-denatured
CMVLacZ (10 kb), UV-crosslinked in presence of various concentrations of DR9NP.
The resulting DR9NP-crosslinked CMVlacZ preparations were named D0 (UV-
irradiation in absence of DR9NP, lane 1), D8 (in presence of 10-8 M DR9NP, lane 2), D7
(10-7 M DR9NP, lane 3), D6 (10-6 M DR9NP, lane 4) and D5 (10-5 M DR9NP, lane 5).
(B) Fraction of DR9NP-crosslinked CMVLacZ (empty circles) and percentage of residual
ß-Galactosidase (ß-Gal) reporter activity (black circles). The intensity of all bands shown
in (A) has been quantified by densitometry. The percentage of crosslinked DNA has been
calculated for each vector by dividing the intensity of the dsDNA by the sum of the
intensities of the dsDNA and ssDNA signal. The reporter gene activity was determined
by transiently transfecting CV-1 cells with equal amounts of the different preparations
and by measuring the expressed ß-Gal with a chemiluminescent reporter gene assay
system. The percentages of reporter gene activity have been normalized by dividing each
activity by the one measured for D0, which is defined as 100%. The average number of
crosslinked DR9NP molecules per plasmid has been calculated mathematically. If we
assume that the DR9NP molecules are crosslinked on pDNA following the rules of
Poisson's distribution, then the probability p to have n crosslinks is defined as p(n,L) =
(L
n
 / n! ) * e-L, where L = average number of crosslinks. For p=0, L= -ln{p(0)}, where
p(0)=1 – (% crosslinked DNA / 100), which corresponds to the probability to have no
crosslinks. (C) Illustration of the three classes of possible molecules in crosslinked
preparations. The reporter gene activity of CMVLacZ without any crosslink (left), with
DR9NP crosslinked outside the reporter gene (center) and with at least one crosslink in
the LacZ gene (right). Symbols: +++, active; -, inactive.
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Figure 4. The activity of DR9NP-decorated reporter plasmid is enhanced in
presence of GR. (A) Experimental outline. At time point 0h, CV-1 cells cultured in 24-
wells plates were infected either with AdGFP (Mock) or AdGR both at MOI = 14. Cells
were rinsed (15h) and subsequently lipofected (19h) with either  10 ng uncrosslinked
CMVlacZ (D0) or 10 ng DR9NP-crosslinked CMVlacZ (D6). 100 ng uncrosslinked
CMVLuc were added to each transfection cocktail as an internal reference. Cells were
harvested (48h) and the activities of ß-Gal and Luc were determined simultaneously with
a chemiluminescent reporter gene assay system. Typical measured values were 106 - 107
RLU / mg protein for LUC and 105 – 106 RLU / mg protein for ß-Gal. (B,C,D)
Histograms representing normalized ß-Gal / Luc values. (B) Enhancement of reporter
activity for the DR9NP-decorated CMVlacZ in presence of GR. (C) Monitoring the
activity of the adeno-transduced GR. After infection either with AdGFP (Mock) or AdGR
at MOI = 14, CV-1 cells were lipofected with 300 ng MMTVLacZ, where the reporter
gene LacZ is under the control of the GR inducible MMTV promoter (construct 3 in Fig.
2A). After incubation in presence or absence of Dex, the cells were harvested and the
reporter gene activities were quantified. In absence of GR, Dex has no influence on the
reporter gene activity and only basal levels of ß-Gal are detectable (bars 1 and 2). In
contrast, in presence of GR, Dex mediates a 80-fold enhancement of reporter expression
(compare bars 3 and 4), indicating that GR is expressed and is functional. The presence of
GR in the infected cells has been also confirmed by immunodetection studies (our
unpublished data). (D) Comparison of D0, D5 and D6 reporter activities in absence of
GR or in presence of GR and GR(Ala). Results in (B) and (C) are the averages (± SD) of
3 independent experiments. Symbols and abbreviations: h, hour; MOI, Multiple Of
Infectivity; ß-Gal, ß-Galactosidase; Luc, Luciferase; M, MMTVLacZ; Dex,
Dexamethasone; empty bar, Mock infected; shaded bar, AdGR infected; hatched bar,
AdGR(Ala) infected.
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Figure 5. The nuclear accumulation of DR9NP-decorated plasmid DNA is enhanced
in presence of GR. CV-1 cells cultured on slides were infected with AdLacZ (Mock),
AdGR or AdGR(Ala) at MOI 14 and subsequently lipofected with Rhodamine-labeled
D0 or D5. The experimental time schedule was the same as described in Figure 4. Cells
were fixed with 4% Formaldehyde and imaged with a confocal laser scanning
microscope. The resulting images were wide field pictures of central optical sections. For
the  quantitative evaluation, the original coloured pictures were converted to black and
white pictures, so that Rhodamine-labeled vectors appear like punctuate white signals.
(A) Confocal microscope image of CV-1 cells lipofected with Rhodamine-labeled D5
without any infection. Arrows indicate examples of cells with clear nuclear signals. Scale
bar: 50 µm. (B) Histogram of evaluated pictures as in (A). Percentage of CV-1 cells with
nuclearly localized D0 or D5 under different conditions. For each condition 5 pictures
were taken randomly. For the quantitative evaluation, the cellular localization of signals
within 150 cells (30 cells for each picture) has been determined. The cellular localization
of the signals has been subdivided into three classes: cytoplasmic, perinuclear or nuclear.
Representative examples of each class are shown in Fig. 6A. The reported percentage is
the average (±SD) of percentages of nuclear signals. The details of all counted signals are
reported in Table 1.
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Figure 6. Bi- and tri-dimensional viewing of nuclear localized plasmid DNA after
transfection. CV-1 cells cultured on slides were infected with AdGR and subsequently
lipofected with Rhodamine-labeled D5. Cells were fixed with 4% Formaldehyde and
stained with acridine orange to visualize nuclei and general cellular structures. Cells were
imaged with a confocal laser scanning microscope. The images are composites of 35
optical sections obtained at 200 nm intervals through the Z-axis of the cells. Rhodamine-
labeled vectors appear like punctuate red signals. (A) Wide field confocal microscope
image. The rectangle highlights a cell with 3 apparent nuclear localized signals. Closed
arrows indicate examples of perinuclear localized signals. Open arrows indicate examples
of cytoplasmic localized signals. (B) Enlargement of the cell highlighted in (A). Dashed
vertical lines define a 3.5 µm broad portion which has been rotated clockwise by 90
degrees through the Y-axis of the cell and is projected in (C). Dashed vertical lines define
a 4 µm broad portion which has been rotated clockwise by 90 degrees through the X-axis
of the cells and is projected in (D). The yellow arrows indicate the different projections of
a nuclear localized signal. Scale bars are 10 µm (A) or 5 µm (B, C, D).
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3.2. PAPER 2: "VECTORS FOR GENE DELIVERY"
Book chapter in Gene Therapy for Rheumatoid Arthritis, Ed. S. Gay , 2000,
Humana Press
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VECTORS FOR GENE DELIVERY
Sandro Rusconi & Maurizio Ceppi
Inst for Biochemistry
UNIFR Pérolles
1700 Fribourg, Switzerland
sandro.rusconi@unifr.ch
In: Gene Therapy for Rheumatoid Arthritis, Ed. S. Gay , 2000, Humana Press
Foreword
Gene therapy bases its rationale on the
transfer of genetic components (genes
or fragments thereof) into somatic cells,
with the aim of preventing, correcting,
or healing various types of disorders.
After this introductory sentence you ex-
pect us to start telling you some of the
marvellous achievements in setting up
the tools that allow this transfer. How-
ever, before entering into the intricate
details of vectorology please allow us
the following clear-cut statement: “as of
today there is no perfect or general
vector for gene therapy and there won’t
be probably any in the foreseeable
future”. We hope that with this
statement in mind, it will be easier for
the readers to understand why there is
still such a multitude of seemingly
disparate efforts in establishing
appropriate vehicles for the gene
transfer.
Therefore, the efficacy of gene therapy
largely depends on the properties of the
chosen ‘vector’ for gene transfer and
expression. The reader should be also
reminded that there is still some
ambiguity in the denomination ‘vector’
because this concept can be understood
either as the mere cis-elements that
compose the transferred sequence (that
is the nucleic acid sequence
arrangement) or as the vehicle/method
which is utilised for the transfer of the
required gene.
1. PROBLEMS INFLUENCING
VECTOR'S CHOICE
1.1 Nucleic acids as medicine:
megadaltons instead of kilodaltons
In gene therapy the drug is a segment of
either DNA or RNA and this imposes
major constraints in the delivery. In
conventional pharmacology the drugs
are molecules of limited size (hundreds
of Daltons) that either freely enter into
cells due to their lipophilic character or
are hydrophilic and destined to either
act in the extracellular space or to be
imported through specific biological
channels. The classical pharmacological
drugs are designed to act over a
relatively short time and their
therapeutic concentration is usually
controlled by re-administration. A
termination of the administration results
in a dilution and termination of the
pharmacological effects. Nucleic acids
do not share many of the above proper-
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ties: they have a large molecular size (1
megadalton for a segment of 1500 base
pairs), are destined to work in the cell
nucleus but are neither lipophilic, nor
can count on a physiological import
system. Once delivered into the nucleus
they either integrate and persist for the
rest of the cell’s life or are maintained
episomally for variable amounts of
time. Therefore, the usual
pharmacological strategies only
marginally apply to the delivery of these
monstrous molecules. For instance, in
order to render them permeable to the
cell membrane, one has to either
compact them into lipid-containing
particles or into viral envelopes or
capsids. This means that the units of
delivery are no longer single, soluble
molecules but relatively large (100-500
nm) and only partially soluble aggre-
gates. This latter aspect makes the work
with nucleic acids as medicines very ar-
duous and still poorly reproducible in
the complexity of a living organism. To
conclude these considerations we will
mention that in the jargon of the gene
therapists, the transferred gene is also
usually referred to as the 'transgene'.
The use of this term will hopefully sim-
plify the reading of the further para-
graphs.
1.2. Correcting disorders derived
from  loss-of-function
or gain-of-function
Genetic and acquired disorders result
from an imbalance of metabolic func-
tions, which are ultimately controlled by
the genetic layout of the affected cells.
The nature of the delivery vector and
the properties of the transgene will
largely depend on whether the therapy
is aimed at inhibiting or supplementing
(or enhancing) metabolic functions.
In most monogenic disorders, the phe-
notype is caused by a single loss-of-
function that depending on the hyerar-
chical position of the affected gene can
cause a simple or a very pleiotropic de-
fect. For instance in cystic fibrosis or in
muscle dystrophy, the lack of function
of the corresponding genes results in
rather circumscribed phenotypes. In this
case the therapy shall be aimed at the
organs that cause the most debilitating
symptoms. Thus, it may be necessary to
count on a rather well targeted delivery
of the therapeutic supplemental gene.
When trying to correct another mono-
genic disorder such as lack of factor
VIII, the vector does not necessarily
need to be targeted to the original tissue
(the liver), since the corrective factor
will be secreted virtually from any
targeted tissue.
When trying in general to compensate
loss-of-function disorders, the level of
gene transfer will also not necessarily
need to be 100% since in most cases a
small percentage of cured cells will
exert a corrective function (see also
under 1.5). Therefore, there will be
lower  requirements in terms of
efficiency of gene transfer on the
chosen vector. For these reasons,
monogenic disorders, though relatively
rare and unattractive from the marketing
point of view, have received a fair
amount of attention by academically- or
industrially-based gene therapists. On
the other hand, when trying to control
disorders derived from gain-of-function
such as most hyper-proliferatory dis-
eases (cancers, auto immune disorders
etc) it will be more important to reach
transfer levels close to 100% or to en-
sure at least that the transfected cells
initiate a feed-back control on the still
untransfected partners and produce a
'bystander effect' (1,2). Thus, the type of
vector and the construction of the trans-
gene have to be adapted to this task.
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1.3. The choice of cis-elements:
constitutive or regulated expression
The first level at which the properties of
a vector are defined is the assembly of
the regulatory and coding elements. In
most of proof-of-principle experiments
in which the transgene was a reporter
gene, the promoter of choice was taken
from the panel of conventionally strong
constitutive champions (CMV, RSV or
SV40). These promoters could be also
considered for clinically valid
therapeutic vectors, although their
strength is strongly cell-specific.
Therefore, in 'second generation'
experiments we have witnessed the use
of tissue-specific promoters, although
with erratic results (3-6). In fact, the use
of a genuinely tissue-specific control
would circumvent the need of precisely
targeting the delivery, since the
regulation would be brought at the
transcriptional level. However, our
understanding of tissue specificity of
transcription is restricted to relatively
short cis-acting elements, whereas in
chromosomal genes locus regulation
occupies probably relatively extensive
sequences (7,8). This is very relevant,
since the currently available strategies
that ensure long term expression are
based on random integration in the host
genome. This random integration is
different in each individual transformed
cell and leads to unpredictable position
effects that influence the expression of
the transgene (4,9-11).
As learned from conventional
transgenic animal models obtained by
pronuclear microinjection (in which the
transferred DNA also randomly
integrates), in the majority of the cases
the transgenes are silenced, and only a
fully equipped locus is 'protected' from
these erratic influence of the flanking
regions.
Such large DNA segments are not com-
patible with the packaging capacity of
most current vectors, therefore we are
momentarily 'condemned' to use surro-
gate mini-regulatory elements (12,13).
For some disorders, another important
goal is the search of bio-sensing cis-
regulatory elements that can respond to
metabolic status such as hypoxia
(14,15), glucose levels (16), etc. These
elements will be indispensable in the as-
sembly of artificial glands that are de-
signed to respond to natural balances of
metabolites, thereby producing factors
such as insulin or Epo in
physiologically relevant and
homeostatically controlled amounts.
Finally, an interesting collection of ex-
ternally controllable cis-elements can be
found in the literature, such as
promoters that can be regulated by
insect hormones (17), steroid
antagonists (18-20), rapamycin or
tetracycline derivatives (21,22). The
advantage of these systems is that the
action of the transgene can be
pharmacologically regulated. These
have been used with variable success in
animal models, where the
administration of the external drugs was
shown to exert the anticipated effects on
the gene expression (18). Four
parameters are important in these
vectors: a) the magnitude of control, b)
the potential for immunogenicity of the
regulatory factor, c) the cross-reaction
of the controlling drug with resident
metabolism, d) the half-life of the drug,
the regulatory gene product and the
target gene product which altogether
determine the rapidity of the onset and
fading of the response. The systems that
use vertebrate regulators such as re-
ceptor mutants that respond to steroid
antagonists have some advantage in
their low immunogenicity, but have
some disadvantage in potential cross-
reaction with resident receptors. On the
other hand, the immunogenicity of the
popular tet-regulatory system, which
has a high magnitude of regulation but
utilises a procaryotic regulatory factor,
has not yet been fully assessed. This
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means that so far there is still a lot to
optimise in this field and that no perfect
system is yet available.
1.4. The three fundamental questions
in gene delivery:
efficiency, specificity and persistence
1 gram of tissue contains an average of
1 billion cells and the interstitial
passages are rarely larger than 150-200
nm. These numbers should suffice to
illustrate the first big problem in gene
delivery: efficiency of transfer. To this
we should add the non-specific binding
of particles by the extra-cellular matrix
and the consequent dilution of active
principle. Finally, we should remember
that there is no specific import for
nucleic acids though the cell membrane
and through the nuclear envelope (see
1.1 and 1.8). Therefore, it becomes
evident that the best current vehicles are
bio-particles that have naturally evolved
the capacity to solve many of these
problems: the viruses (see 1.8; 2.2 and
2.3).
Since it is not always possible to guar-
antee absolute specificity of gene
expression (see above 1.3), we have
sometimes to delegate the specificity to
the delivery particle. To this aim several
strategies have been designed (see 2.3.2
and 2.4.2 below).
Finally we should consider that when
correcting chronic or progressively de-
generative disorders, the transgene must
persist and be active over a very long
time, preferably for indefinite time. This
is one of the most difficult tasks. Even
if we manage to concoct the best
regulatory regions that will prevent
gene silencing through random
integration in the genome (see 1.7), we
cannot prevent the transformed cells to
be lost by natural shedding such as in
rapidly growing epithelia. This forces us
to choose among two alternatives. a)
target master stem cells that will be
maintained throughout the renewal of
the target tissue; b) accept the
discomfort of periodical re-
administration of the transgene. With
partial exception of the bone marrow,
and in spite of the spectacular recent
advances in stem cell research, we are
not yet able to guarantee the efficient
transformation of pluripotent precursors
and so far we are forced to consider re-
administration as inevitable for the long
term correction of most chronic disor-
ders. Re-administration brings with
itself all the unpredictabilities of the
immune reactions, specially but not
exclusively when working with viral
vectors (see below). Thus, we can
affirm that at the state of the art, there is
still no single or clear solution to the
long term treatment of chronic
conditions.
1.5. Efficiency of transfer and
persistence of expression: not always
100% required
The former paragraph could lead a pes-
simist to the conclusion that chronic
conditions will never be treatable by
gene therapy. The good news come
from the fact that for some conditions
such as haemophilia (23) or cystic
fibrosis and many others, a fraction of
the natural levels of expression is
sufficient to achieve therapeutic effects.
When attempting to correct those
conditions, it is sufficient to guarantee
between 5 and 10% of transformation of
the target tissue. Therefore, the
corresponding vehicles do not need to
sustain a 100% transfer, although the
problem of persistence of the
transformed cells is still relevant.
On the other hand, there are treatments
that require neither high efficiency nor
specificity nor persistence of the trans-
fer. One example is DNA-based vacci-
nation (24,25), where a permanent
effect is achieved upon transient
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expression of a transgene. Another
spectacular example is the corrections
of critical limb ischemia (26) where the
ectopic and transient expression of
naked DNA injected intramuscularly
brings about sufficient VEGF signal to
rescue ischemic tissue. Analogous
protocols are currently considered for
treatment of other cardio-vascular
conditions where a short term treatment
can produce long lasting beneficial
effects. These examples should suffice
to illustrate the concept that efficiency,
specificity and persistence are not a
major requirement in all cases of gene-
assisted therapy, and this is of en-
couragement for all those who believe
in this type of interventions.
1.6 Specificity: strategies,
satisfactions and frustrations
The choice of the physical strategy for
delivery determines the requirements to
the vehicle. Gene transfer can be
achieved ex vivo (for example in bone
marrow explants) and in this case, the
specificity and immediate
immunogenicity (see below) of the
vector are less relevant. In other
protocols, specificity can also be
achieved in vivo by local application
(inhalation, double balloon catheter,
intramuscular, intratumoral, brain
stereotactic injection etc.). Also in this
case the properties of the gene carrier
are focussing on efficiency rather than
on specificity, since this latter is defined
by the administration protocol. Only in
systemic delivery (intravenous
injection) the problem of targeting be-
comes relevant. In the simplest cases,
one can exploit the natural tendency of
some organs such as liver and kidney to
accumulate particulated drugs (27-30).
However, these organs are not necessar-
ily the targets in all disorders and this
poses some serious problems of read-
dressing the accumulation of the trans-
gene-bearing vehicle (see targeting
under 2.3.2 and 2.4.2). The problem is
double, since, not only one has to devise
specific docking elements on the carrier
particles, but one has also to circumvent
non-specific accumulation in the above
mentioned organs (see one example in
(31) ).
1.7. Persistence and integration: to be
or not to be? In either case you'll pay
a fee
As commented above a reproducible
and efficient method for inserting the
transgene into a defined chromosomal
location is still lacking. This situation
causes two side-problems: gene
silencing from position effects (see also
1.3) and random insertional
mutagenesis (that will be further
commented under 3.2). Therefore there
is not yet a satisfactory protocol that
ensures indefinite persistence of the
transgene without causing the two
above-mentioned effects. This problem
will be solved only when either locus-
specific integration can be achieved (as
originally hoped with the AAV vectors
(32,33) ) or when self-replicating and
segregating artificial chromosomes (34)
will be available. Until then, when we
choose an integrating vector for our
therapeutic protocol, we must be aware
that we shall benefit of its potential to
make the gene to persist but at the same
time to randomly disturb resident func-
tions and to be subject to uncontrollable
position effects.
Of course we can choose to utilise a
non-integrating vector such as an RNA
virus, an Adenovirus (35) or an Herpes
virus (36).  In these cases, the transgene
persists for a while but is not co-
replicated when the host cell
proliferates and is destined to be lost.
Therefore the dilemma is in the choice
of accepting the benefits of
chromosomal integration and pay the
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fee of random silencing and insertional
mutagenesis, or avoid these latter but
paying the fee of non-permanent
transformation.
1.8. Viral versus non-viral, who wins?
The non-viral modes of gene transfer
include physical, chemical and bio-
chemical protocols. Among the physical
methods direct injection of naked DNA
(37), pressure-mediated transfer (38,39),
electrically enhanced transfer (40,41)
and biolistic bombardment (42,43) have
showed various degrees of efficiency.
The chemicals/biochemical protocols
include the use of cationic lipids and
different compaction methods and each
company or research lab claims to have
the best results, although it is rare to see
direct and extensive cross-comparisons
in the published papers. Recently, the
biochemical methods in which viral
proteins are included to spike liposomes
(33,44-46) have received increased
attention, since they seem to promise
enhanced gene transfer coupled to
increased targeting. Although we can
observe that in cell cultures DNA can
be delivered to more than 99% of the
cells, only a minor portion (3-10%) will
ultimately transiently express the
transgene (our unpublished results).
This discrepancy is due to the second
barrier in gene transfer: the nuclear
envelope (37,47). It is hypothesised that
the majority of the transfected DNA is
degraded in the cytoplasm and is not
reaching the nucleus. Among the
strategies that have been recently
proposed to reinforce this second
transfer we shall mention the attempts
to link to the DNA oligopeptides
containing nuclear localisation
sequences (48,49, and references
therein). In our laboratory we are
exploring the possibility of using
resident nuclear shuttles to favour the
import of the transgenes into the target
cells. The strategy has been named
SMGD (Steroid Mediated Gene Deliv-
ery, Figure 1) and aims at using intra-
cellular nuclear receptors as ferrying
vectors for the transfected DNA.  Nu-
clear receptors such as the steroid re-
ceptors have nanomolar affinities for
specific ligands and are nucleophilic,
therefore appear to be excellent candi-
dates for efficient and specific shuttles
for macromolecules that display et their
surface the cognate ligands. To achieve
this, we had to devise strategies to
chemically 'decorate' the transgene with
ligands. So far, we have obtained en-
couraging results with model com-
pounds interacting with the glucocorti-
coid receptor (Ceppi et al. in prepara-
tion).
2. SMALL PARADE OF
CURRENTLY POPULAR
VECTORS
2.1 The simplest way:
delivering naked  or 'biochemically
dressed' DNA
2.1.1 Structures and methods
Attempts to deliver naked DNA by
direct intramuscular injection have been
pioneered by J Wolff (47,50, and refer-
ences therein). The initial encouraging
results have prompted a series of emu-
latory protocols aimed at exploiting this
simple delivery system for gene-based
vaccination. The mechanism of DNA
uptake by muscles is only tentatively
explained (50) has so far precluded the
rational design of improvements of the
efficiency. In spite of its simplicity, this
method has been the first ever bringing
clinically relevant results in the
treatment of critical limb ischemia with
ectopic expression of VEGF (26).
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Besides these straightforward but highly
empirical approaches, a number of ways
to enhance the uptake of DNA has been
adapted from the long standing experi-
ence with cell-cultures. This has led to
the reformulation of various combina-
tions of liposomes, lipoplexes and poly-
lipoplexes (51) and to other
sophisticated receptor-ligand mediated
internalisation systems (52). These
efforts have built an important platform
of technologies for general and specific
gene transfer, although the efficiency of
these transfer methods is still several
logs inferior to the virally-based modes.
In general, to achieve anything between
0.1 and few percent of transfected cells,
one has to employ a 10exp[4] to
10exp[5] molecules per cell, whereas
with viral transfer 1 to 10 particles per
cell can give up to 100% transfer. This
poses also the problem of the kinetics of
delivery. When added in one shot, the
excess molecules are either lost, de-
graded or can generate non-specific im-
mune reactions. Therefore, non viral
transfer usually implies the continuous
delivery over a period of time. Recent
advances in the design of bio-
degradable microspheres or
encapsulating biolpolymers that
progressively liberate trapped DNA has
shed new perspectives on this strategy
(28,53-56). Still, when working with
non-viral delivery, one has to deal with
the meager efficiency of nuclear
transfer of the transfected DNA (see
above). This problem subsists inde-
pendently to the delivery method and is
one of the reasons of the large ratio (ac-
tive molecules per cell) that is required
to achieve reasonable transformation
rates. Finally, there is no specific
mechanism for integration into the host
genome, and this relegates non-viral
transfer to the realm of transient
treatments, unless some strategy to
improve integration or persistence of
the transgene can be established. For
these reasons, transfer of naked DNA is
currently only indicated for DNA-based
vaccinations, which nevertheless held a
phenomenal potential in the prevention
of infectious diseases and cancer (25).
2.1.2 Targeting
The use of microsphere-aided delivery
(see above) can help in specific aug-
mentation of local concentration of the
active molecules, thus providing a sort
of topical specificity. Other ways of
simple targeting are offered by the body
anatomy which permits molecular treat-
ment of mucosae, epithelia etc. When
injected systemically, each liposome
formulation displays minor differences
in the preferences of organ
accumulation (28,30). However, the
common tendency is that formulations
accumulate in liver and kidney and are
not able to pass blood-brain barrier
(36,57). This natural condition will be
an important hurdle in designing
specifically targeted formulations.
Drastic protocols such as liver by-pass
(31) are good for a proof-of-principle of
how to short-circuit this problem but are
too laborious and invasive to be
clinically implementable in a
generalised manner.
A major effort has also been devoted to
the identification of molecular compo-
nents of the endothelial zip-code system
(58,59). Once understood, this tissue-
specific marking of the vascular system
could provide an elegant system of local
accumulation of active particles.
At the cellular level, the best candidates
protocols in particle targeting are the
ones that exploit affinity of ligands for
surface receptors (52). Some important
improvements have been achieved by
preparing 'virosomes' (33,44) in which
viral proteins are decorating the surface
of liposomes. If proven to be reproduci-
bly infectious and compatible with large
scale preparation, these hybrid particles
can pave the way to the generation of
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"artificial viruses" that may enjoy the
advantages of in vitro assembly and
avoid some of the disadvantages of bio-
logically assembled viruses
(commented under 2.5.3).
2.1.3 Advantages and disadvantages
The production of in vitro assembled
particles can be better controlled and
guaranteed be devoid of adventitious in-
fectious pathogens. Therefore these for-
mulations are pharmacologically safer
than biologically assembled infectious
particles. Secondly, there will be less
constraints on the size of the transgene,
which is a major problem in
biologically assembled viral particles
(see 2.3). Furthermore, the composition
of synthetic particles can be designed to
be devoid of immunogenic elements.
Therefore, in vitro formulations
containing nucleic acids can be
considered suitable for multiple re-
administrations, a property that is not
yet guaranteed with the most popular
viral vectors. The lack of immunogenic-
ity should however not be overempha-
sised, because DNA that has been con-
ventionally amplified in bacterial
systems (the most convenient basis of
molecular large scale preparation)
acquires some intrinsic immunogenicity
because of the loss of methylation of
CpG -rich sequences (60-63) and
perhaps also because of some other
newly acquired bacterial methylation
patterns (62, our unpublished
observations). Those problems can be
theoretically solved, although there is
no clear picture of the mid- and long-
term reaction of an immune-competent
organism subjected to repeated DNA
delivery that does not go through the
digestive tract.
The major disadvantage of non viral
transfer methods remains obviously the
intrinsic low efficiency of transfer. The
improvements of the last five-ten years
have increased the transfer rate perhaps
by a factor of ten, but there are several
logs to catch up with the viral transfer
(see 2.1.1). If no breakthrough comes
into the field, one has to assume that
non-viral gene transfer will be restricted
to the treatment of conditions where
efficiency of the transfer is not a crucial
parameter.
2.1.4 Suitability and examples
Paradoxically to its intrinsic
inefficiency, non-ßviral gene delivery
has been the first treatment to
demonstrate unequivocal therapeutic
value. This occurred in the seminal
experiments by the research team of Jeff
Isner (26), in which the expression of a
pro-vascularising factor (VEGF)
through simple intramuscular injection
of a suitable recombinant plasmid has
rescued necrotising limbs already in
phase I trials. We are looking forward to
confirmations of these encouraging data
in phase II and phase II trials, as well as
their extension of other treatments in the
cardiovascular field. The trials of Victor
Dzau and colleagues (39) are another
success story in non viral gene-assisted
treatment. Artery bypass based on vein
grafts currently fails in a high
proportion due to the aberrant growth of
the intima, induced by the higher blood
pressure in the transplanted vein. The
team of Dzau has pre-treated the graft
with a simple pressure-mediated gene
transfer and shown that the transferred
genes were able to inhibit the hyper-
proliferation of the smooth muscle cells,
thus reducing significantly the occlusion
of the graft. The transgenes chosen were
either growth-inhibitory genes or decoy-
oligonucleotides that transiently titrate
transcriptional factors that are essential
for the expression of pro-proliferatory
genes.
We conclude this paragraph by men-
tioning the discovery of the interesting
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properties of the herpes viral protein
VP22 (64). This protein is capable of
cell-to-cell transfer and can translocate
into cells even when added to the ex-
tracellular medium. This property ex-
tends to some VP22 chimeric proteins
(65, and references therein). This may
be just the tip of the iceberg of several
new protein-mediated macro-molecular
transfer systems that may solve some of
the current problems of non-viral trans-
fer, provided they can be designed to be
invisible to the immune system.
2.2. Replication-defective and
replication-competent viruses
2.2.1 General features of replication-
defective recombinant viruses.
Viruses have evolved since millions of
years to become professional gene-por-
ters. They can exploit the most sophisti-
cated molecular mechanisms to escape
immune surveillance, to specifically
dock to target tissues, to enter through
cell membranes, to resist intracellular
degradative enzymes, to deliver nucleic
acids to the nucleus or to organise spe-
cialised compartments for genome repli-
cation and expression, to integrate into
the host genome or to remain latent for
several years in host organisms and to
be even passaged through the germ line.
Therefore, there is no better vehicle that
can be envisioned by gene therapists to
efficiently transfer the preferred thera-
peutic gene. Viruses have however a
very nasty property: they are pathogenic
because their capsid proteins are mostly
immunogenic or toxic and their genetic
reprogramming strongly disturbs the
cell metabolism and cause diseases of
various severity. A better knowledge of
the viral genomes has permitted the
distinction of segments necessary for
the packaging into the capsid from those
encoding replicative functions and
capsid or envelope components. This
has permitted to construct viruses that
retain only fragments of their genome
and are debilitated in some pathogenic
functions. These defective viruses need
to be amplified either in specialised
packaging cells or in presence of helper
viruses that provide in trans the missing
functions. The situation is different for
each virus and it would be too intricate
to comment all the sequence
geographies, thus I will take the
example of the adenovirus to illustrate
the steps undertaken to optimise transfer
vectors for gene therapy. The adenoviral
genome consists of 36 kb of linear DNA
with inverted terminal repeats that are
indispensable for replication and
packaging into the capsid (35,66). The
'left' portion (E1/E2 in Figure 2A)
contains the early genes whose
expression is indispensable to prepare
the conditions for genome replication
(66). Other early functions are scattered
in other regions and are dispensable for
replication. The remaining 80% of the
genome is occupied by the late genes,
mostly expressed through the major late
promoter (MLP, Figure 2A) and giving
rise to variegated proteins through
differential splicing. In packaging cells,
the 'early' portion of the genome could
be anchored into the chromosomes and
shown to be functioning in trans. This
permits the growth and assembly of
viral genomes whose early segment is
either missing or substituted by a
transgene of interest (figure 2B). This
scheme has been maintained in all the
viruses of so called first and second
generation. Those recombinant viruses
have proven invaluable to demonstrate
efficient gene transfer in animal models
and also in patients (33,66-68). How-
ever, the remaining leaky segment en-
coding late genes confers a significant
immunogenic potential to those genera-
tion I vectors. Therefore, the expression
in immune competent animals is re-
stricted to few weeks. Several strategies
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have been proposed to reduce this im-
munogenicity (66). The best solution so
far has been offered by the so-called
'gutless' (also called 'helper dependent'
or 'high-capacity' or  'third generation')
adeno-vectors. In these constructs the
entire late region is replaced by a ‘neu-
tral’ DNA segment including the thera-
peutic gene(s) (Figure 2C) and the re-
combinant genome is grown and pack-
aged in presence of a helper virus
whose assembly is repressed by various
strategies (66,67). After careful
purification one can obtain significant
titers of the recombinant vectors that are
minimally contaminated (approximately
10exp[-4]) by the helper virus.
Extremely encouraging results have
been recently reported with these gutted
Adenovectors that were shown to
produce a permanent somatic gene
alteration that can persist for several
months (69,70) even in immunocompe-
tent animals. We are confident that
clinical trials involving gutted viruses
will confirm the compatibility of these
vectors with long term correction by
gene transfer.
2.2.2 Principle of replication-competent
viruses
Several viruses encode early proteins
that interact with ubiquitous tumor sup-
pressors such as P53 or retinoblastoma.
By exploiting this situation, some re-
search teams have developed recombi-
nant viruses that maintain a conditional
replicative potential whose fulfilment
depends on the absence of tumor-sup-
pressor functions. Selective or at least
preferential replication has been
reported for adenoviruses that retain the
E1B gene (71-73), for HSV (74-77) or
other RNA viruses (33). These viruses
are capable of lithic growth in cells that
are missing or underexpressing tumor
suppressors and this property makes
them attractive candidates for tumor
treatments, leading to some interesting
clinical protocols. Only the future will
tell whether these expectations are well
placed and whether these oncolytic
viruses can be safely used either as
stand-alone or as combination-treatment
in tumor therapy.
2.3. bio-weapon 1: DNA viruses
2.3.1 Structures and methods
In the preceding paragraphs we have il-
lustrated the principles behind recombi-
nant Adenoviruses. Therefore we will
not comment further on these develop-
ments. With analogous protocols two
other important DNA viral carriers have
been  designed: the adeno-associated vi-
ruses (AAV) and the herpes viruses
(HSV). These two are distinguished by
diametrically opposite properties. The
recombinant AAV particles have a very
limited packaging capacity (3.5-4 kb)
and integrate the recombinant DNA into
the host genome (32,36,78). The intact
AAV has the capacity of integrating
specifically into a site on chromosome
19 but this property is missing in the
emptied recombinant genomes, which
integrate randomly. In spite of this
random integration, the recombinant-
AAV constructs seem to be refractory to
gene silencing through position effects.
this property is currently attributed to
the AAV terminal repeats that seem to
possess some kind of 'insulator' property
that renders the intervening sequence
rather independent of the integration
context (79). The increasingly simple
protocols for production of r-AAVs and
the extremely low immunogenicity and
toxicity of these particles has prompted
a large number of investigations of
therapeutic gene transfer into small and
large animals (13,80-83). Therefore,
these vectors promise to be a reasonable
choice for the permanent transfer of
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small-sized constructs. The construction
of HSV vectors is more laborious but
offers several advantages. Particularly
interesting is the possibility of
generating recombinant genomes of
very high capacity (up to 150 kb
(33,36,84) ). This opportunity could
permit the transfer of large loci or of
multiple regulatory cassettes for precise
tuning of gene expression.
Recently, an interesting variation on the
theme has emerged: the possibility of
combining the advantages of two inde-
pendent viruses. So for instance hybrid
genomes that combine the great infec-
tious capacity of Adenovectors and the
possibility of integrating the transgene
through a surrogate retroviral transposi-
tion have been proposed (32,33,73,78).
Analogously, hybrid HSV-AAV vectors
that combine the large capacity of pack-
aging of HSV and the integration power
of AAV have also been proposed
(32,33,36,84). These hybrid viral vec-
tors are probably still at their rudimen-
tary stage, but represent exciting devel-
opments in a field that would otherwise
have stagnated over the intrinsic limita-
tions of each individual carrier.
2.3.2 Targeting /retargeting
Every virus has a natural tropism which
is defined by the host molecular
partners required for infection,
replication and packaging. When
working with recombinant viruses the
primary factor is represented by the
infection mechanism. This is dependent
on the match between the cell surface
receptors / co-receptors and the docking
sites displayed at the surface of the
infectious particle. There are essentially
two ways of changing the infectivity
tropism: one is to alter the docking
proteins (for instance the adeno fibres
(68,73,85,86) ) by adding protein
domains that represent ligands for alter-
native receptors; another consist in pre-
paring Janus-type ligands that on one
side interact with the original docking
structure and on the other face they pro-
vide a new ligand (85). The latter strat-
egy has the advantage of maintaining
the same general structure of the vector
and is probably preferable to the former
strategy which can alter the properties
of the capsid and requires specially
engineered packaging cells for the
amplification of the recombinant vector.
Both strategies have been tried in
cellular and animal models, but the
success has been so far only moderate,
since the new specificity imposed a high
price in infectivity. These approaches
will require substantial improvement
before being suitable for serious clinical
trials.
2.3.3. Advantages / disadvantages
The recombinant DNA viruses men-
tioned above share several advantages.
They can be grown at very high titers
(between 10exp[9] to 10exp[11] per
ml), they have a very stable genome and
they can efficiently infect both
proliferating and non proliferating cells.
This latter property is certainly the most
attractive for somatic gene transfer,
since many therapies would require the
gene transfer in cells that do not
proliferate such as neurons, endothelial
cells etc. Adeno and HSV do not
integrate their genome, and this can be
considered as both advantageous and
disadvantageous. The persistence as
unintegrated genomes makes them
immune to position effects (good news)
but also implies the dilution of the
recombinant genome upon proliferation
of the infected cells (bad news). The re-
combinant AAVs combine the capacity
of integrating in the host genome and a
partial resistance towards position
effects through their inverted terminal
repeats (ITRs). However, a major
disadvantage of AAV is the restricted
packaging capacity (at most 4 kb of
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foreign DNA) while r-Adenos of the
first generation can carry transgenes
around 8 kb and 'gutted' adeno can
accommodate more than 30 kb or HSV
episomes can arrange up to 150 kb
(36,84). The immunogenic potential of
the DNA viruses is different fore each
vector, with r-Adenos of the first
generation being the most immunogenic
and thus suitable only for unique
treatments and for treatment of
disorders where a certain immune
reaction may even be advantageous
such as cancer.
2.3.4. Suitability and examples
The literature on pre-clinical studies
with DNA viral vectors is extremely
wide and covers all possible disease
models from cancer to infectious
disorders. However, only very few
reports bring convincing evidence of
potential up-scalability to large animals.
For several years, hyper-critical circles
used to say that gene therapy has until
now "only been good to cure mice". In
spite of these sarcastic affirmations,
progress in some areas has been rather
spectacular. The natural tendency of
adenoviruses to accumulate in the liver
after systemic administration had
prompted a series of interesting trials
for the correction of metabolic disorders
(33,66,73). Unfortunately, the tragic
events linked with one of these trials
(87-91) has slowed down the experi-
mentation with further improved Ade-
novectors, including gutted adenos. On
the other side, the transduction of re-
combinant AAV expressing blood clot-
ting factors has been demonstrated to
provide long term therapeutic benefits
in both small and large animal models
(33,80,82,83,92). Similarly, the use of
HSV and gutted Adenoviruses in pre-
clinical tests has shown convincing per-
sistence of gene expression in many tis-
sues (33,82). Thus, DNA-viruses re-
main powerful tools for the treatment of
both acute and chronic conditions.
2.4. bio-weapon 2: RNA viruses
2.4.1. Structures and methods
RNA viruses tend to have a relatively
small and less stable genome compared
to DNA viruses. The unstability of
RNA genomes is mainly due to the lack
of proofreading in RNA replication and
this results in error rates in the range of
1 mistake in 10'000 nucleotides. Most
RNA viruses can only transiently persist
within a cell, but the retroviruses can
convert their RNA genome into a cDNA
which is transposed into the host ge-
nome and thus can be virtually carried
indefinitely within the host cell. This
latter property has immediately evi-
denced retroviruses as preferred vectors
for gene transfer. The inspiration of the
ability of retroviruses to carry foreign
genes certainly comes from the early
discovery of murine and avian
oncogenic retroviruses which can
transduce cellular protooncogenes. The
first attempts to construct engineered
retroviruses was indeed based on
murine retroviruses. The essential cis-
elements that must be carried along with
the engineered genome are the long
terminal repeats (LTR), the packaging
region and the primer annealing
sequence (93). The genes for the
necessary proteins (reverse
transcriptase, capsid and envelope pro-
tein) can be transferred to host chromo-
somes in packaging cells. Once trans-
fected with a plasmid encoding the
engineered retroviral backbone, these
packaging cells can produce infectious
particles at titers around 10exp[6]
10exp[7] (93). The engineering of
recombinant lentiviruses is more
laborious since several regulatory
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proteins must be concertedly expressed
to allow packaging (33,36,94).
Currently the best system seems to be
via co-transfection of trans-
complementing plasmids (95). The
complexity of the procedure is such that
it cannot fully exclude the arising of re-
combinant genomes that are capable of
autonomous replication (RCP, replica-
tion competent particles). The latent
chance of the emergence of these RCPs
has certainly strongly hampered the
clinical implementation of protocols
with lentiviral backbones, and this in
spite of the obvious advantage of
lentivirus over other retroviruses: their
capacity of infecting quiescent cells
(94).
2.4.2. Targeting /retargeting
The viral envelope (consisting of host
cell membrane spiked by env proteins)
can be virtually substituted or
engineered at will. The currently used
winning horse is the VSV env protein
(93). Several attempts to engineer the
env proteins to change their docking
specificities have been reported. These
attempts have invariably resulted in
lower titers since there is little way to
rationally redesign docking surfaces.
Given the improvements in recombinant
virus handling we can anticipate that
new specificities will be obtained
through genetic selection from
combinatorial libraries rather than
through rational design. Alternatively,
changes of tropism can be obtained as
for the Adenovirus, by coating a general
env-protein with bifunctional ligands
that on one hand mask the natural
specificity and on the other hand contact
alternative docking sites (see also
2.3.2). Unfortunately, it is not
guaranteed that all docking sites will be
suitable for viral internalisation, which
is a rather complicated process.
2.4.3. Advantages / disadvantages
The major advantage of retroviral back-
bones is that they can be assembled free
of viral-protein coding genes. This
means that after integration a properly
engineered provirus will not encode for
immunogenic viral proteins, thus guar-
anteeing a long term survival of the
transduced cell. The major advantage of
lentiviruses is the capacity of infecting
non-proliferating cells (see also 2.4.1), a
situation which is advantageous for the
treatment of differentiated tissues or
slowly turning-over tissues such as the
CNS, endothelium, or bones.
A major disadvantage of retroviruses is
the low titer (two to four logs lower
than the one of DNA viruses. A
standard in vivo therapy may require
between 10exp[12] an 10exp[13]
infectious particles. For DNA vectors
this means processing volumes of less
than 1 litre, whereas tens to hundreds of
litres may be necessary to obtain the
same amount of retroviruses. This
situation may become a strong
drawback for the industrial preparation
of clinical materials. The more subtle
disadvantage of retroviruses is the
intrinsic low-fidelity of replication.
Assuming 1 mutation for every 10 kb,
every third copy of a 3 kb transgene se-
quence will contain at least one mis-
match. This can result to the loss of the
biological activity in a large fraction of
the transduced cells. Finally, as with
AAV systems, the random integration
into the host genome and the rather lim-
ited (about 9 kb) packaging capacity
pose problems of long-term
maintenance of gene expression (see
above 1.7) and of insertional
mutagenesis.
2.4.4. Suitability and examples
The very first bona fide gene therapy
clinical trial (treatment of ADA defi-
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ciency (96) ) was indeed performed
with recombinant murine retroviruses.
Since then retroviruses have been used
to carry compensatory genes or toxic
genes in many clinical protocols.
However none of these attempts could
demonstrate significant therapeutic
effects, specially because the
experiments were confined to phase I
status, where the major focus is the
measurement of side-effects. From this
point of view the retroviruses have at
least confirmed their relatively low
toxicity. The major draw-back of
recombinant murine retrovirus is their
inability to infect quiescent cells, but
this property is rescued in the lentiviral
systems (see 2.4.1), which have shown
to be equally versatile and yet capable
of infecting post-mitotic cells (94). The
improvements in assembly will soon
permit to produce recombinant
lentiviruses guaranteed  free of
replication-competent particles, and this
will open their option for clinical trials.
Finally, the simplicity of the original
murine retroviral system already used in
the very first (and essentially failed)
gene therapy attempts by Anderson or
Bordignon (96,97), has not discouraged
the team of Alain Fischer who
ultimately has brought the very first
historical example of permanent radical
cure of a genetic disorder by the ex-vivo
transduction of bone marrow transplants
with vectors supplementing the IL2-
receptor gene which is defective in a
rare form of SCID (82,98). The two
young patients of Dr. Fischer are the
best results that gene therapy has scored
within its short adventure, and for the
public opinion are more worth than
thousands of pre-clinical 'mouse
therapies' or reporter assays. Resting on
these encouraging indications, gene
therapy based on simple viral
vectorology may indeed pave the way to
several efficacious intermediate clinical
applications. Whether or not this
strategy will persist in the long term, it
depends only on further improvements,
but we can say that, if wisely used, the
today's vectors already have a
significant potential for the treatment of
chronic disorders.
2.5. Macromolecular weapons: a
short click at the
www.fantasticoligo.com site
2.5.1. Structures and methods
Gene therapy does not require the trans-
fer of full genetic complements to be-
come effective. Small gene fragments,
in form of synthetic single stranded or
double stranded oligonucleotides can
exert a powerful control on gene expres-
sion. The most popular form of oligonu-
cleotide-assisted therapy is done with
antisense sequences that are destined to
block either the maturation or the trans-
lation of specific mRNAs. Protocols
aimed at tumor control through oligonu-
cleotides that down regulate the produc-
tion of protoonogenic proteins or anti-
apoptotic factors have achieved the
phase III (99). A further sophistication
is the use of oligonucleotides that have
a ribozyme function (100) and are able
to specifically hydrolyse target mRNAs.
Also double stranded 'decoy' oligonu-
cleotides that compete with genomic se-
quences by binding transcription factors
have been successfully used in the clinic
(39).
A further level of sophistication is
represented by oligonucleotides that are
capable of forming triple-helix
structures with specific target
sequences. For triplex formation, the
only a-priori requirement for the target
sequence is that purines and
pyrimidines should be segregated on the
two strands (101, and references
therein). Oligonucleotides capable of
repressing or stimulating gene ex-
pression have been designed in this
- 95 -
manner (102,103). Recently, triplex
forming oligos capable of guiding mole-
cules that induce specific repair of
target sequences have been proposed
(104). The major disadvantage of
oligonucleotides is their short survival
within a cell. Therefore, these protocols
imply either continuous supply of the
therapeutic oligo or single treatment of
acute conditions. Several modifications
of the desoxy-ribonucleotide backbone
have been proposed to augment the
resistance of oligos toward degradative
nucleases. The most spectacular
modification is probably the so called
PNA (protein-nucleic acid) backbone,
in which the carrier polymer no longer a
phosphate-ribose chain (105,106, and
references therein). A great advantage
of PNA is certainly the lower negative
charge of the polymer chain, which
enormously stabilises either the double
or the triple stranded structures that it
undergoes with target sequences. PNA
has been shown to be easy to handle and
to permit also accumulation into cellular
subcompartments such as mitochondria
(107), a condition which is not met by
other nucleic acid transfer methods. We
are certain that PNA will become the
polymer of choice for the locus-specific
accumulation of active principles.
Finally, a bizarre family of chimeric oli-
gonucleotides called 'chimeroplasts' or
'chimeraplasts ' has been reported to be
capable of inducing specific gene repair
at remarkable frequency (104,108-111).
Although the exact mechanism and the
prerequisites imposed on the chimeric
oligonucleotide structure remain poorly
rationalised, the efficiency with which
repair if single base pair mutations has
reached up to 40% under some circum-
stances (109). There is still some con-
troversy about the general applicability
of the chimeraplasty, about its real effi-
ciency and safety, and about the number
of molecules that must accumulate into
a cell to obtain satisfactory frequencies
of repair. Also, for a certain time this
technology could not be reproduced by
research teams independent of the
original discoverer. However, recent
reports indicate that this technique may
have finally worked in different
laboratories (111). If indeed broadly
applicable, chimeraplasty may become
the method of choice for the treatment
of many disorders caused by small
genetic defects (single nucleotide
mutations). The greatest advantage of
this technique is that it promises to be
exquisitely site-specific, thus to
generate much less if at all undesired
side-effects. if chimeraplasty can be
ameliorated to achieve close to 100%
repair, it may become a technique that
reopens the option of germ line
interventions, with all the bulky
complement of ethical problems
accompanying this dossier. In fact,
taken at face value, chimeraplasty is the
only available technology that fully
deserves the denomination of 'gene
therapy' in its strict sense.
2.5.2. Targeting
Owing to its principle, oligonucleotide-
mediated therapy does not need to be
strictly targeted at the level of delivery,
since it is intrinsically aimed at precise
interactions through base-pairing. How-
ever, given the very high costs of oli-
gonucleotides, it will certainly be phar-
macologically advantageous if the
therapeutic oligos can be specifically
delivered or accumulated to target
tissues. We envisage that our SMGD
protocol (see 1.8) can be also adapted to
ameliorate the accumulation of
oligonucleotides in a tissue-preferential
manner. Local delivery is so far the
most popular option, although
decoration with specific ligands for
internalising receptors has been very
promising, at least with liver-directed
therapy with chimeraplasts (112).
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2.5.3. Advantages / disadvantages
Compared to intact genes, oligonucleo-
tides have molecular sizes of several or-
ders of magnitude smaller (few thou-
sands Daltons). This smaller size
renders them more similar to
conventional drugs, although they do
not easily permeate through cell
membranes. A second advantage is that
oligonucleotides do not require bio-
synthetic steps for their preparation, an
thus can be more easily formulated
under pathogen-free conditions.
The main disadvantage is that oligos
tend to be degraded after a relatively
short time, implying that the treatment
of persisting diseases will require
repeated administrations. The
chimeraplasts are indeed able to
produce a permanent effect but their
current range of correction is limited to
single point mutations.
2.5.4. Suitability and examples
In spite of the limitations mentioned
above, oligonucleotides have been
maintaining their therapeutic promises.
After transfer of double stranded decoy
oligonucleotides that titrate
transcription factors controlling cell
proliferation, V. Dzau and colleagues
has been able to significantly reduce the
incidence of intima-growth in vein
transplants (39). In this case, the merit
of the approach is that the transient
treatment is sufficient to bring a
permanent effect, since it sustains the
non-degenerative adaptation of veins to
the higher pressure. We have also
already mentioned the spectacular
correction rate obtained in rat  models
of a liver disorder (109) with chimero-
plasty. Here also, a short treatment per-
mits a long term therapeutic effect. Sev-
eral antisense oligo approaches against
protooncogenes are now in advanced
clinical testing. However, we have to
wait these tests to assess the validity of
this approach. Personally, we are quite
sceptical about these anti-cancer thera-
pies, specially since they don't offer a
priori any bystander effect (see 1.2) and
therefore seem less suitable for tumour
eradication.
3. FINAL HURDLES AND
CONCLUSIONS
3.1. Immune response and re-ad-
ministration
This book is focussing on the molecular
treatment of a disorder with auto
immune and inflammatory components.
In this kind of treatment it is absolutely
imperative that the procedure should not
imply reagents or manipulations that
could unnecessarily activate the cellular
or humoral immune system be it
specific or innate. Therefore, the work
with viral vectors of any kind should be
considered with substantial caution.
However, also non viral gene transfer
could pose several problems when using
entire genes, due to the innate reaction
against unmethylated CpG-rich motifs.
In general, re-administration is almost
unavoidable with the current technology
and this does not simplify the
foreseeable clinical protocols for the
treatment of chronic disorders with
inflammatory components. Thus, until
better control on the short-term and
long-term immunogenicity of gene
delivery systems can be obtained, gene
therapy cannot be considered as a first
priority for this class of disorders where
it could ultimately exacerbate the
outcome instead of bringing a
therapeutical effect (113).
Finally, the immune system poses a
problem also when the vectors them-
selves are clean of any pro-
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inflammatory properties. In fact, in
some genetic loss-of-functions the
resident gene is either deleted or totally
non-functional. In this cases, the
expression of the healthy gene product
can lead to tissue rejection since it is
detected as a 'foreign' antigen by the
host immune system (23,69,114). For
these cases, tolerisation strategies must
be devised before considering gene
transfer.
3.2. Safety considerations, from RCP
to insertional mutagenesis
The immune reactions are not our sole
hurdle in virally-assisted gene transfer.
Some capsid proteins, while providing
useful functions such as translocation
and protection from degratative en-
zymes, are themselves toxic and can
produce adverse reactions. In fact, most
biologically assembled viral
preparations contain a large excess
(between 10 and 100 fold) of non
functional viral particles. these particles
can significantly contribute to the
overall toxicity of the gene transfer
procedure. Also we have mentioned that
no biological recombinant viral
preparation can be a priori guaranteed to
be free of adventitious recombinants
that have re-acquired viral genes
sufficient for autonomous replication
(the so-called RCPs, see 2.4.1). Even if
the incidence of RCP can be reduced to
less than one event in 10exp[14], this
may pose serious constraints and cause
severs costs augmentations to the indus-
trial preparation of clinical materials.
The vectors that currently permit
permanent transfer do not have ways of
controlling the site of integration of the
transgene. Thus, every cellular integra-
tion event is in principle an insertional
mutagenesis event. At the somatic level,
the large amount of insertional mutage-
nesis has the potential of generating
pro-tumorigenic cells by activating
protooncogenes. This relegates the use
of integrating vectors for the treatment
of life-threatening diseases, where the
risk of generating a secondary tumor is
still acceptable. The random
mutagenesis generates another dilemma
if the gene delivery vector transforms
germ cells. In this case we would have a
large number of aditional mutations that
would be inherited to subsequent
generations, and the potential benefit for
the treated individual could become a
strong disadvantage for his/her progeny.
These dilemmas will be solved when we
will be able to assemble vectors that can
permanently deliver transgenes in
specific chromosomal locations.
Considering the current pace of
progress, this goal should not be so far.
3.3. Pulling it all together
If a pragmatic reader had the patience to
read all the good and bad news about
the existing and prospected vectors,
he/she may ask: but after all, which vec-
tor/delivery is suitable for my goal?
In the Table 1 we summarise the suit-
ability of the currently available gene
transfer methods (columns) for different
types of treatment. the number of '+'
signs indicates qualitatively the suitabil-
ity of a given combination. We hope
that this synopsis may help in the choice
of the most appropriate combination.
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TABLE 1
Table 1 Qualitative assessment of suitability of delivery vehicles
Application ADV AAV HSV HIV OLI PEM GUN LIP
Vaccination /prevention ++  (+)  (+)  (+) - - +++  (+)
Acute treatment ++ - - - ++ - - +
Chronic treatment - ++ ++ +++  (+) - - +
In vivo local delivery ++ ++ ++ ++ ++ + ++ +
In vivo systemic delivery + + + + + n n +
Ex vivo delivery ++ + + +++ ++ ++ + ++
Single administration +++ +++ +++ +++ + + + +
Repeated administration  (+) +  (+) ++ +++ + +++ +++
Treat loss-of-function +++ +++ +++ +++ + ++ + ++
Treat gain-of-function  (+) + + + +++ - - +
Gene correction - - - - +++ - - -
Symbols: Adv, Adenovirus vectors; Aav, adeno-associated virus vectors; Hsv, Herpes
virus vectors; Hiv, lentiviral vectors; Oli, oligonucleotides; Pem, pressure or electro-
poration mediated delivery; Gun, biolistic or macroinjection; Lip, lipoplexes or poly-
plexes. Symbols for suitability: -, not suitable; (+) questionable; +, hardly suitable; ++ ,
offers several applications; +++, excellent choice; n, does not apply. Most of the
indicated degrees of suitability are justified in this chapter.
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3.4. Outlook:
Will rudimentary vectorology with all
its troubles
survive the emerging challenge of
stem cell therapy?
Stem cell research has been booming in
the last months. Primordial cells for al-
most all the tissues, including the CNS,
have been characterised and the major
hope is that the ex vivo cultivation of
those may permit tissue regeneration for
various treatments (115,116). The most
spectacular observation is certainly that
some stem cells seem to be able to
trans-determination, that is to give rise
to differentiated cells that are different
than the donor tissue (97,116,117).
Many of the claims and reports in this
field are not yet even in the peer-
reviewed literature but have been
propagated through press releases or
news-agencies despatches. According to
them, in a foreseeable future, it should
be possible to explant bone marrow
cells and later reconstruct muscle,
nerves, bones, epidermis and other
types of tissues from this original popu-
lation. The mechanisms that govern the
maintenance of the pluripotency and the
commitment towards one or another
lineage are still obscure, but they are so
intensively studied that we can
anticipate major breakthroughs within
the next few years.
3.4.1 The worst and best case scenario
Being able to culture stem cells without
losing their pluripotency and to then de-
termine their commitment would pave
the way to autologous organ reconstruc-
tion that could cure an immensely large
number of degenerative disorders. If the
disorder has a genetic component, the
corresponding correction could be
easily achieved with conventional gene
transfection ex-vivo and corresponding
selection of pre-characterised
recombinant cell clones. This would
render obsolete most of the efforts to
obtain high efficiency gene delivery
vectors. Those latter would only be
required for those cases where a cell
therapy is not indicated, such as in acute
treatments or corrections of gain-of-
function disorders.
Thus, taken at face value, cell therapy
has all the hallmarks to become a supe-
rior procedure for the treatment of
chronic conditions. The worst that could
happen is when patents and human am-
bitions would transform the noble ten-
dency towards a better therapy into a fe-
rocious battle between gene therapists
and cell therapists for the best slices of
the health market.
The balance of the odds for gene or cell
therapy could change drastically if gene
correction procedures such as chimero-
plasty (see 2.5.1) would confirm their
efficacy or if hybrid vectors (see 2.3.1),
artificial viruses (see 2.1.2) or coher-
ently integrating vectors (see 1.3, 2.3.3,
3.1) would make the long-sought brak-
through. If any of those tools would be-
come generally applicable, then gene
transfer in vivo would certainly remain
competitive, since it implies lower
costs, shorter intervention time and
probably also lower invasivity than cell
therapy.
3.4.2. A final homily for gene transfer
We have recapitulated the aims and ef-
forts towards developing tools and
methods for efficient gene transfer.
When taken pessimistically, one could
imagine that the few, but highly cele-
brated, therapeutic achievements are
condemned to remain anecdotal and one
wonders why should the scientists con-
tinue in this direction that has brought
more frustrations than successes. From
the point of view of fundamental re-
search, the answer is refreshingly sim-
ple. While trying to solve the engineer-
ing problem of gene therapy, scientists
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have re-discovered and partially solved
old neglected problems related to cell
biology, virology, molecular transport
and degradation, cell surface properties,
etc. Furthermore, the pre-clinical efforts
have produced vectors that are phe-
nomenal tools for fundamental research.
Gene transfer vectors are already
considered for hit-and-run gene
alteration procedures that will permit
temporally and spatially controlled gene
knock-out or knock-in in experimental
animals, a situation which is laborious
to achieve with conventional
transgenesis. Furthermore, the gene
transfer vectors open the way to the
experimentation with primary cell
cultures, that are notoriously refractory
to biochemical gene transfer. This will
permit the functional study of genes
under semi- or fully-physiological
conditions and a better understanding of
the intricate interactions between gene
products. Therefore, gene therapy has
brought an immense flood of novel
knowledge that will substantially accel-
erate the overall progress in
experimental life sciences.
From the clinical/pragmatic point of
view, the heroic efforts towards gene
therapy must be regarded as necessary
steps that have broken the ice and paved
the way towards more efficacious mo-
lecular therapies. We should not forget
that any technological progress, from
the aeroplane to the computer, has
started with prototypes that seem almost
ridiculous when compared with the
today's opportunities. But without these
glorious steps we would still be devoid
of such marvellous achievements and
would still be gasping intellectual
conjectures about their feasibility
instead of enjoying their concrete
advantages. So, let's keep going and be
proud thereof!
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FIGURE 1, The two barriers for gene transfer and the principle of SMGD
A. In gene transfer the genetic material must pass two barriers: the cell membrane (a)
and the nuclear envelope (b). Only a small proportion of the transferred nucleic acids
undergoes nuclear transfer (compare thin arrow under b and thick arrow under a).
B. The concept of steroid mediated gene delivery. Conventional DNA (N), even if
abundantly transfected (thick arrow marked a1) is only poorly translocated into the
nucleus (thin arrow marked b1). Ligand-decorated DNA (marked H, where ovals with
bar represent covalently linked ligands) is equally well transfected (a2) but better
transported to the nucleus (b2) by the nuclear receptor that binds to the cognate ligand.
This approach permits the selective facilitation of nuclear uptake of transgenes. In our
laboratory we have proved this concept with model systems involving the
glucocorticoid receptor (Ceppi et al. in preparation).
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FIGURE 2: Genomes of wild type and recombinant adenovectors
A. The genome of wild type adenoviruses see text for references) is a linear 36 kb
dsDNA flanked by inverted terminal repeats (hatched boxes) that are necessary for
DNA replication and packaging. The indispensable early functions are E1 and E2 that
are encoded by a 25% left portion of the genome (see E1 and E2). The late functions
(capsid protein) are encoded by the remaining part and are mostly transcribed through
the major late promoter (MLP) that gives rise to alternatively spliced mRNAs (broken
dotted line), The late portion of the genome encodes in the opposite direction the viral
DNA polymerase (dotted arrow pointing to left).
B. Replication-deficient adenovectors of the first generation are deleted in the early
region and can be grown in packaging cells that provide the E1 and E2 functions. The
deletion allows the accommodation of up to 8 kb of foreign DNA.
C. 'gutless' or 'high-capacity' adenovectors retain only the ITR region and can accom-
modate up to 32 kb of foreign DNA. These recombinant genomes can only be packaged
in presence of a helper vector (see text).
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4.1. SUMMARY OF PROPERTIES OF SELECTED STEROID DERIVATIVES
Name Hor Spacer1 DNA binder KD(nM Dex) NTI2 EOT3
CR6Et Cort 6 EtBr 570 + +
DR23Et Dex 23 EtBr 2100 - nd
DR4Sn Dex 6 Spermine 370 - nd
DR8Sn Dex 8 Spermine 17 + +
DR13Sn Dex 13 Spermine 390 - nd
DR9NP Dex 9 Psoralen 100 ++ +++
DR13NP Dex 13 Psoralen 20’000 - nd
Dex Dex no no 3.7 +++ -
Abbreviations: Hor, hormone; Cort, cortisol; Dex, dexamethasone; EtBr, ethidium
bromide; KD, thermodynamic equilibrium dissociation constant (measured by
scatchard analysis of competition curves); NTI, nuclear translocation inducer (see
Fig.1 of Paper1, chapter 3.1.); EOT, enhancement of transfection (see Fig. 4 of
Paper1, chapter 3.1.).
1. Spacer length is comprising all the atoms separating the hormone moiety and the
DNA binder function.
2. Qualifiers for NTI: -, no significant nuclear translocation (NT) with concentrations
above 500 nM; +, more than 75% NT by 500 nM; ++, more than 75% NT by 50 nM;
+++, more than 75% NT by 5nM.
3. Qualifiers for EOT: nd, not determined; +, 1.5-2 fold increase but without possible
internal transfection reference; ++, 2-4 enhancement without possible internal
reference; +++ 2-4 enhancement measured with internal reference.
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